The Editorial Staff of the Journal o/Immunology is grateful to the many ad hoc reviewers who served...

The Editorial Staf f of the Journal o/Immunology is grateful to the many ad hoc reviewers who served the Journal and its contributors. We acknowledge our appreciation

for their efforts.

C. A. Abel Marilyn Etzler E.D. Kilbourne James Allen R. Evans T. Kindt D. W. Alling N.B. Everett S. Kinsky Elliott Alpert Michael Fanger S . J . Klebanoff E. Appelta R.S. Farr Katherine Knight R. Austrian Alexander Fefer P. Kohler R. W. Baldwin I .J . Fidler M.E. Koshland G. L. Bartlett Richard Finkelstein R.M. Krause J. R. Battisto Pamela Fraker Donald Krueger M. A. Bean M.M. Frank R.T. Kubo Matilda Benyesh- Rolf Freter P . J . Lachmann

Melnick Herman Friedman E.M. Lance Gideon Berke Yochanen Friedman A. R, Lawton David Berman D.L. Gasser G. L, Le Bouvier John Bienenstock R.K. Gershon R.A. Lerner R. V. Blanden Irma Gigli B.B. Levine K. J. Bloch A.L. Goldstein Lawrence Levine Viktor Bokisch Gerald Goldstein R.R. Lindquist Tibor Borsos Irving Goldschneider W.R. Loewenstein M. W. Brandriss E .S . Golub David Lagunoff Irving Broder Otto Gotze C.C. Lushbaugh J. D. Capra G.A. Granger Zoltan Lucas Thomas Carey Ira Green G.B. Mackaness Renata Cathou A. Grossberg I .C .M. MacLennan W. G. Ceglowski D.L. Groves R.G. Mage S. D. Chaparas F.C. Grumet Benjamin Mandel M. W. Chase M.G. Hanna, Jr W.J . Mandy J. M. Chiller Geoffrey Haughton Dean Mann T. K. Choi D. Hawkins L.A. Manson C. Christian P. M, Henson Mart Mannik W. A. Clyde Glora Heppner D. M, Marcus J. H. Coggin J .F . Heremans M.R. Mardiney, Jr. Carl Cohen M.S. Hirsch W.R. McCabe Z. A. Cohn Beulah Holmes-Gray Charles McCall D. G. Colley J. Hoppner R.T. McCluskey S. R. Cooperband C. Hunttey Pat McConahey Andre Cruchaud Michael Howe D.D. McGregor W. P. Dannenberg, Jr. Ernest Jawetz Ross McIntyre J. M. Davie F. Jensen David McKean S. Day A.G. Johnson Ian F. C. McKenzie P. B. Dent Colin Jordin C.F. McKhann S. D. Douglas E.A. Kabat Hans Meir T. C. Douglas B.D. Kahan R.C. Mellors Sheldon Dray Nathan Kaliss Thomas Merigan K. M. Drummond Shogo Kano Jiri Mestecky D. C. Dumonde F.S. Kantor Felix Milgrom R. W. Dutton M.J . Karnovsky Percy Minden H. Dvorak J . M . Kehoe R.I. Mishell T. S. Edgington G.E. Kenny Goren Molter David Eidinger R.S. Kerbel G.E. Moore R. D. Ekstedt R.F. Kibler V.L. Moore W. L. Elkins Marion Kies J .W. Moorhead

2282

1974]

D. C. Morrison R. M. Nakamura S. G. Nathenson R. W. Newcomb George Naft A. L. Notkins A. Novgorodsky P. C. Nowell R. C. Nowinski Victor Nussenzweig M. B. A. Oldstone R. P. Orange Abraham Osler Zoltan Ovary J. J. T. Owen Joseph S. Pagano J. W. Palm Jon Palmer W. P. Parks W. O. Parks C. R. Parish P. Y. Paterson N. N. Pearsall R. A. Phillips C. W. Pierce R. N. Pinkard J. J. Pruzansky A. M. Prince J. Quagliata M. C. Raft Fred Rapp R. A. Reisfeld

AD HOC REVIEWERS

J. S. Remington Heinz Remold Ross Rocklin John Rocky N. R. Rose W. C. Rose D. Rosenstreich Russell Ross Werner Rosenau N. Rothfield D. S. Rowe Derek Rowley S. W. Russell J. Sandson Sam Salvin G. W. Santos M. D. Scharff R. W. Schlesinger J. C. Schwab Alec Sehon Stewart Sell J. M. Sheagren Sidney Shutman Hutton D. Slade R. T. Smith Ralph Snyderman Alan Solomon C. Sorg L. E. Spitler J, F. Stevens E. H. Stonehill

W. J. Streilein R. S. Simmons Norman Talat D. W. Talmage R. N. Taub W, B. Terry G. A. Theis C. W. Todd D. E. Thor T. B. Tomasi G. M. Tomkins Amar Tung D. Turbergen Robert Walderman S. S. Wachtel Roy Walford B. H. Waksman K. S. Warren Benedict Wasitauskas I. L. Weissman J. V. Wells R. W. Wheat R. C. Williams, Jr. C. B. Wilson A. C. Wang J. R. Wunderlich G. P. Youmans J. B. Zabriskie B. Zbar Nathan Zvaifler Bruce Zwilling

2283

AUTHOR INDEX

Abdou, Nabih I., 1931 Abel, Carlos A., 1517, 1623 Abrahamsohn, Ises, 1931 Ackermann, Roll, 2063 Ackermann-Schopf, Christl, 2063 Adam, A., 2028 Adkinson, N. Franklin, Jr., 1426 Adler, Frank L., 1981 Albini, Boris, 444 Albrecht, Thomas, 1680 Aldo-Benson, Marlene, 1793 Alexander, Alice, 1757, 1762 Alter, Harvey J., 1100 Alving, Carl R., 1949 Alvord, Ellsworth C., Jr., 392 Ammann, Arthur J., 617 Amos, D. Bernard, 1190 Amsbaugh, Diana F., 404, 1042, 2020 Angala, Epifania, 2148 Annable, C. R., 1 Annes, Vera C. dos Santos, 722 Arend, William P., 451 Argaman, Meir, 649 Armstrong, Martine Y. K., 706 Arru, Efisio, 1674 Asofsky, Richard, 2202 Aspinall, Richard L., 1741 Auer, Ignaz O, 320 Austen, K. Frank, 351, 664, 970 Azzolina, Luigi, 822

Badger, Alison M, 1435 Baker, Henry J., 124 Baker, Phillip J., 404, 1042, 2020 Balch, Charles M., 79, 87 Bankert, Richard B., 1782 Baram, Peter, 1705 Barme, Michel, 987 Baron, Samuel, 1589 Barth, Roll F., 756, 858 Barthold, David R., 9, 1042 Bazin, Herv~, 1035 Bech-Nielsen, Steen, 1051 Becker, Elmer L., 2047, 2055 Beckers, Andr6e, 1035 Beldotti, Lorraine, 410 Benacerraf, Baruj, 855, 1158, 1181, 1329 Bennett, John E., 2260 Berkowitz, Jesse M., 1008 Bernstein, I. D., 1267 Bernstein, Joel M., 488 Beyer, Carol B., 1920 Biberfeld, Gunnel, 413 Bienenstock, John, 1997

Billing, Ronald J., 1124 Binaghi, Ruben A., 722 Bismuth, Main, 2036 Bitter-Suermann, Dieter, 935 Blair, Phyllis B., 439, 693 Blakeslee, Dennis, 2148 Blanden, Robert V., 496 Bobrove, Arthur M., 520 Bokisch, Viktor A., 627 Bona, C., 2028 Bonavida, Benjamin, 433, 926, 1231, 1308 Borduas, A. G., 1264 Borel, Yves, 1793 Borella, Luis, 836 Boros, Dov L., 996 Borsos, Tibor, 979, 1107 Brade, Volker, 1115, 1845 Brandtzaeg, Per, 1553 Bratcher, Raymond L., 1337 Braude, Abraham I., 2184 Bridges, S. It., 812 Brodey, Robert S., 1051 Brown, Geoffrey, 420 Buckley, Rebecca H., 376 Budzko, Delia B., 1839 Buerki, Heinz, 1961, 2154 Buttrick, Peter, 862

Calderon, Jesus, 1804 Calvanico, Nickolas J., 162 Campbell, Priscilla A., 1407 Capra, J. Donald, 633 Carpenter, Charles C. J., Jr., 996 Casarett, George W., 178 Casper, Elizabeth A., 2126 Cassell, Gail H., 124 Cederqvist, Lars L., 1605 Ceglowski, Walter S., 2077 Chapman, Harold A., 555 Charman, Howard P., 1250 Chedid, L., 2028 Cheers, Christina, 1535 Chema, Samson, 919 Chen, James P., 1920 Chino, Jen Wei, 627 Chiller, Jacques M., 370 Chong, Christine A., 1337 Christian, Charles L., 627 Christian, Elizabeth S., 1582 Chused, Thomas M., 285, 641 Ciorbaru, R., 2028 Claflin, J. Latham, 1747 Clagett, James A., 1660 Claman, Henry N., 115, 333, 849, 960

2285

2286 INDEX [voT.. 112

Clancy, Robert, 1997 Clem, L. William, 941 Clem, William, 633 Clinton, Bruce A., 1741 Cochrane, C. G., 573 Cohen, Ada, 683 Cohen, Benjamin E., 359 Cohen, Edward P., 1285, 1296 Cohen, Stanley, 1540 Colten, Harvey R., 905, 1107 Conant, Robert M., 919 Cone, Robert E., 1535 Conrad, Robert E., 17 Cook, Richard G., 583 Coonrod, J. Donald, 2193 Cooper, H. Rebecca, 1407 Cooper, Max 1)., 555 Cooper, Nell R., 339, 866, 1667 Cooperband, Sidney R., 1435 Coppola, Peter R., 488 Cottier, Hans, 1961, 2154 Crandal], Richard B., 770

Dailey, Morris O., 1526 Damais, C., 2028 Daniels, Charles A., 2087 Darnule, Tukaram V., 311 Das, Saroj, 107 Davie, Joseph M., 1747, 2202 Dawson, Jeffrey R., 1190 Day, Eugene D., 607 Daynes, Raymond A., 2111 Defendi, Vittorio, 2241 de Landazuri, M. Ortiz, 2102 de Landazuri, Manuel Ortiz, 26, 37, 1231 del Guercio, Paolo, 427 ])ella-Porta, A. J., 656 DePamphilis, Jean D., 520 de Souza, Celso M., 1369 Despont, Jean-Pierre J., 1517, 1623 Diamond, Richard D., 2260 Dierich, Manfred, 935, 1766 l)imitriu, A., 2028 Dixon, Frank J., 241,564 Doherty, Peter C., 1548 Doff, Martin E., 855, 1329 Dorrington, Keith J., 949 1)otson, Carroll Ray, 1149 Dray, Sheldon, 1337 Driscoll, Bernard F., 392 Dunham, Edward K., 1329

Edidin, Michael, 2210 Egan, Harwood S., 63 Ekstedt, Richard D., 63 Elakovich, Stella D., 1920 Elfenbein, Gerald J., 2166 Elin, Ronald J., 737

Engelfriet, C. P., 1444 Engelhard, Warren E., 1660 Engers, Howard D., 293 Epstein, Lois B., 617, 1131 Evrin, Per-Eric, 137 Esteves, Maria B., 722

Fahey, J. L., 2102 Fahey, John L., 26, 37, 433 Fair, D. S., 201 Fanger, Michael W., 1971 Farrar, John J., 430, 1244, 1613 Feizi, Ten, 145 Feldman, Joseph D., 79, 87, 1861, 1867 Ferrone, Soldano, 1766 Fidler, Isaiah J., 1051 Fidler, John M., 1891 Fierer, Joshua, 2184 Fine, Douglas P., 763 Finley, Fred, 2184 Fishman, Marvin, 1981 Floersheim, Georg L., 1508 Forsgren, Arne, 1177 Fox, Alfred E., 1394 Fox, Roy A., 1861, 1867 Frank, Michael M., 398, 641, 2260 Franklin, Edward C., 871 Freedman, Henry H., 1394 Friedman, Herman, 1452, 2077 Fritz, Thomas E., 1467

Galili, Uri, 1628 Gately, Maurice K., 168 Getfand, Erwin W., 792 Gerin, John L., 1100 Gershon, Richard K., 101,215, 260, 546 Gery, Igal, 215 Ghanta, Vithal K., 266 Gilbertsen, Richard B., 376 Gilden, Raymond V., 1250 Gipson, Thomas G., 2087 Giuliano, Vincent J., 1494 Glade, Philip R., 675 Gleich, G. J., 201 Goetzl, Edward J., 351 Gold, Jon W. M., 1100 Goldberg, Melvin L., 1347 Goldenberg, Kim, 1008 Golub, Edward S., 1891 Gomard, Elisabeth, 1477 Good, Robert A., 1383 Goodman, Joel W., 883 Gorezynski, Reginald M., 47, 533, 1815, 1826 Gordon, Francis B., 2126 Gormus, Bobby J., 770 Gotoh, A., 416 G6tze, Dietrich, 1643 Graham, Theodore C., 1,508

19741 INDEX 2287

Granger, Gale A., 2111 Grant, J. Andrew, 897 Grant, R. A., 1219 Grayston, J. Thomas, 540 Greaves, Melvyn F., 420 Green, Ira, 398, 641, 1589, 2166 Greenland, Timothy, 2036 Gregory, Douglas S., 1861, 1867 Grey, Howard M., 1517, 1952 Grobter, Peter, 2154 Grossberg, Allan L., 911, 1774 Groves, David L., 1582 Grubb, Ande1~ O., 1420 Guttmann, Ronald D., 1594

Haakenstad, Alan O., 1939 Habicht, Gail S., 804 Hakomori, Sen-ltiroh, 424 Hamaoka, Toshiyuki, 855 Hamlin, N. Martene, 266 H~mmerling, Gtinter J., 1726, 1734 Hamparian, Vincent V., 919 Hanly, W. Carey, 877 Hanna, M. G., Jr., 1026 Hanson, Michelle, 1250 Hardin, John A., 641 Hargreaves, R. E., 1267 Hauptman, Stephen P., 2274 Hellstr6m, I., 1267 HellstrSm, Ingegerd, 1987 Henson, P. M., 573 Henson, Peter, 1383 Henson, Peter M., 2047 Heremans, Joseph F., 1035 Herzenberg, Leonard A., 520 Hess, Max W., 1961, 2154 Heusser, Christoph, 2094 Hierholzer, John C., 987 Hiramoto, Raymond N., 266 Hoffsten, Phillip E., 564 Hogg, James C., 1094 Holland, Paul V., 1100 Hollander, Carel F., 2271 Holmes, Beulah, 1383 Horn, Denis J., 862 Horn, Joanne, 326 Hood, Leroy, 633, 941 Horn, Robert G., 746 Hsu, Long S., 2047 Huang, Eng-Shang, 528 Huang, Yung-Tsun, 528 Hughes, John I t , 919 Hunter, Robert L., 1526 Hurd, Eric R., 1494

Ibrahim, Ali Bin, 387 Ignarro, Louis J., 210 Imai, M., 416

Ingraham, Joseph S., 17 Inman, Franklin P., 229 Isersky, Chaviva, 1909 Ishizaka, Kimishige, 1078, 1652, 1685 Ishizaka, Teruko, 1078 Isliker, Henri, 2094

Jackson, Lula, 1589 Jackson, Peter, 96 Jaroslow, Bernard N., 1467 Jasin, Hugo E., 1494 Johnson, Alice R., 511 Johnson, John S., 555 Johnson, Joseph E., III, 1322 Johnson, Judith P., 1329 Jordan, George W., 728 Joseph, Kenneth C., 1949 Joubert, James R., 1094 Jutila, John W., 1698

Kabat, Elvin A., 145 Kakimoto, Kiiehi, 1373 Kakinuma, Mitsuaki, 830 Kaliner, Michael, 664 Kamo, Isao, 2013 Kane, Michael A., 2260 Kang, Yoon Se, 162 Kano, Kyoichi, 410 Kaplan, Melvin H., 2135 Kapp, Judith A., 1181 Kappler, John W., 1271 Kateley, John R., 1452 Katz, David tt., 855, 1158 Kedar, E., 2102 Kedar, Eli, 26, 37, 1231 Kersey, John H., 862 Kettman, J., 1139 Kierszenbaum, Felipe, 1839 Kies, Marian W., 392 Kim, Young Tai, 1255, 2002 Kind, Leon S., 1609 Kindt, Thomas J., 601 Kishimoto, Tadamitsu, 1685 Knecht, Eva, 1839 Knight, Katherine L., 877 Knobel, Hans R., 2094 Kolb, Hans-Jochem, 1508 Kondo, Kazunari, 546 K6nig, Wolf gang, 1652 Koprowski, Hilary, 2013 Kourilsky, Francois M., 2036 Kouttab, Nicola M., 1698 Krause, Richard M., 627 Kreisler, J. Miguel, 151 Kronvall, GSran, 1955 Krueger, R. G., 201, 1415 Kudo, Ralph T., 1952 Kulczycki, Anthony, Jr., 1909

2288 INDEX [voL. 112

Kunkel, H. G., 1277 Kuo, Cho-Chou, 540 Kurashina, S., 416 Kyle, R. A., 201 Kyriakos, Michael, 468, 478 Kysela, Susan, 9

Laissue, Jean, 1961 Lance, Eugene M., 546 Lande, Saul, 1565 Lane, Mary Ann, 439, 693 Langman, Rodney E., 496 LaRoque, Robert L., 468 Laskov, Reuven, 683 Lausch, Robert N., 1680, 1900 Laux, David, 1900 Lazda, Velta A.~ 1705 Leclerc, Jean Claude, 1477 Lederer, E., 2028 Lee, Gerald D., 1115, 1845 Lehman, David H., 241 Lelchuk, Rosalia, 1578 Lerner, Kenneth G., 1508 Leskowitz, Sidney, 107 Levis, William R., 1488 Levy, Jean Paul, 1477 Levy, Joshua, 2063 Lichtenstein, Lawrence M., 897 Lichter, Edward A., 877 Lieberman, Rose, 1747 Lightbody, James J., 890 Lin, Nancy, 919 Lindsey, J. Russell, 124 Little, J. Russell, 812 Little, K. D., 812 Litwin, Stephen D., 1605 Liu, Teh Yung, 649 Lloyd, Kenneth O., 311 Loos, Michael, 935 Loughman, Barbara E., 430, 1244 Liischer, Ernst F., 1201, 1211 Lyons, Susan F., 1452

Ma, Wai-Sai, 1387 Magoc, Terry J., 1741 Magro, Albert M., 1757, 1762 Mahmoud, Adel A. F., 222, 996 Main, Luiz C. Sauerbronn, 1369 Malloy, William F., 1609 Mandel, Mark A., 996 Manni, Jorge A., 1578 Mannik, Mart, 451, 1939 Manning, Dean D., 1698 Manuel, Yves, 2036 Marquardt, Hans, 241 Martens, Barbara L., 1407 Matuhasi, Tyoku, 462

Mauch, Peter, 812 May, Joseph E., 2260 Mayer, Manfred M., 168, 1115, 1845 Mayer, Steven E., 511 Mayumi, M., 416 McClatchy, J. Kenneth, 1407 McCombs, Candace, 326 McDevitt, Hugh O., 1726, 1734 McGhee, Jerry R., 266 McMaster, Philip R. B., 1387 Meinke, Geraldine C., 1401 Merigan, Thomas C., 728 Merluzzi, Vincent J., 1435 Metcalf, Donald, 502 Metzgar, Richard S., 376 Metzger, Henry, 1909 Michaelides, Maria C., 1560 Milgrom, Felix, 320, 410 Miller, A. Edgar, Jr., 1488 Miller, Michael E., 1164 Mishell, Robert I., 326 Miyakawa, Y., 416 Molenaar, J. L., 1444 MSller, GSran, 151 Mond, James, 1255 Mookerjee, B. K., 822 Moorhead, John W., 115, 333, 849 Moran, Nell C., 511 Moroz, Leonard A., 1094 Morrison, D. C., 573 Mortensen, Richard F., 2077 Mosier, Donald E., 305 Mullen, Helen, 468, 478 Muller, M. A. C., 1444 Murasko, Donna M., 1680 Musiani, Piero, 1674

Naipaul, Naresh, 852 Naor, David, 2068 Nariuchi, Hideo, 462 Nash, Theodore E., 1500 Natvig, J. B., 1277 Neauport-Sautes, Catherine, 2036 Neva, Franklin, A., 1500 Neveu, P. J., 1264 Niblack, Gary D., 1582 Nicholson, Anne, 1115, 1845 Nielsen, Hans E., 1194 Nilsson, Kenneth, 137 Nilsson, Ulf R., 1164, 1931 Nishioka, K., 416 Norberg, Renee, 413 Nordin, Albert A., 430, 1244 Notkins, Abner L., 2087 Notkins, Abner Louis, 1019

O'Brien, Richard L., 1884

1974] INDEX 2289

Ogra, Pearay L., 488 Ohanian, Sarkis H., 979 Okudaira, Hirokazu, 1652 Okumura, K., 783 Oldstone, Michael B. A., 370, 866 Onoue, Kaoru, 1373 Oriol, Rafael, 2227, 2235 Oroszlan, Stephen, 1250 Osoba, David, 844

Pagano, Joseph S., 528 Paolilli, Patricia, 1884 Papageorgiou, Photini S., 675 Parker, John W., 502, 1884 Parker, Leroy M., 285 Patrucco, Aida, 1578 Patterson, Roy, 1855 Paul, William E., 359, 398, 2166, 2202 Pellegrino, Michele A., 1766 Penn, Gerald M., 1517 Petit, J. F., 2028 Pfueller, Sharron L., 1201, 1211 Phanuphak, Praphan, 115, 849 Philip, Robert N., 2126 Piantelli, Mauro, 1674 Pierce, Carl W., 1181, 1360 Pirofsky, Bernard, 1952 Pizzimenti, Maria C., 1839 Plata, Fernando, 1477 Poirier, Marie France, 427 Poltara, Bernard, 1387 Polley, Margaret J., 866 Pondman, K. W., 1444 Poultar, Lyndall, 822 Pozzuoli, Roberto, 1674 Praissman, Melvin, 1008 Prescott, Benjamin, 404, 1042, 1500, 2020 Pressman, David, 911, 1774 Prester, Marlot, 792 Proctor, Richard A., 1070 Pross, Hugh, 2219 Purcell, Robert H., 1100

Quan, Alice L., 2126 Quie, Paul G., 1177

Rabinowitz, Ruth, 683 Rabinowitz, Stanley G., 1070 R~dl, Jiri, 2271 Rall, Theodore W., 996 Ralph, Peter, 1873 Ramshaw, Ian A., 1548 Rao, V. Srinivasa, 433 Rapp, Fred, 1680 Rasmussen, Lucille E., 728 Reed, William P., 1955 Reeder, Walter J., 63

Reedman, Beverley M., 656 Reese, Alice L., 1971 Reese, Andy C., 1971 Reisfeld, Ralph A., 1643, 1766 Remold, Heinz G., 1571 Resch, Klaus, 792 Ricardo, Manuel J., Jr., 229 Rich, Robert R., 1360 Richards, Frank F., 96, 706, 1565 Richman, Alan Ve, 2241 Rigsbee, Lewis C., 607 Rittenberg, Marvin B., 47 Riviere, George R , 776 Robbins, John B., 649 Rocklin, Ross E., 1461 Rodrick, Mary L., 2094 Roelants, Georges E., 883 RSllinghoff, M., 1718 Rose, Noel R., 965 Rosenau, Werner, 1347 Rosenberg, Gary L., 1019 Rosenberg, Jerry C., 890 Rosenberg, Steven A., 1426 Rosenstreich, David L., 1085 Rosenthal, Alan S., 746, 1085 Rosenthal, J. Thomas, 607 Rosenzweig, Miriam, 877 Roser, J. F., 573 Rosselet, J. P., 2028 Rousset, Monique, 2227, 2235 Rowlands, David T., Jr., 2148 Rubin, Bent, 2219 Rudders, Richard A., 871 Ruddle, Nancy H., 706 Rudofsky, Ulrich H., 1387 Russi, Serena, 1061

Sabbadini, E., 2251 Saieg, Robert G., 594 Salinas, F. A., 1026 Salmon, Sydney E., 1131 Sant'Anna, Osvaldo A., 722 Saunders, David, 2210 Schaefer, Annette E., 1981 Schiff, Richard 1., 376 Schirrmacher, Volker, 2219 Schlesinger, Michael, 683, 1628 Schlesinger, Sondra, 1560 Schoenberg, Melvin D., 1971 Schroeder, Marie-Louise, 1508 Schwartz, Robert S., 410 Scott, David W., 1354 Sen, Luisa, 836 Shands, Joseph W., Jr., 770 Sharp, Gordon C., 468, 478 Sheppard, Laura B., 1190 Shih, Janet C., 607


Shin, Hyun S., 1115, 1635 Shope, Robert E., 260 Showell, H. J., 2055 Showell, Henry J., 2047 Shreffier, Donald C., 965 Shuster, Joseph, 716 Silver, Jonathan, 1190 Silvestre, D., 2036 Singal, Dharam P., 852 Singla, Ore, 756, 858 Siracusano, Alessandra, 1061 Siraganian, Patricia A., 2117 Siraganian, Reuben P., 2117 Siskind, Gregory W., 1255, 2002 Sledge, Carlos, 633,941 Sorokin, Carol F., 675 Spencer, James C., 1322 Spiegelberg, Hans L., 1401 Spitzer, Roger E., 56 Spofford, Bryan T., 2111 Stanton, Thomas, 633 Stashak, Philip W., 404, 1042, 2020 Stavitsky, Abram B., 583, 1971 Steblay, Raymond W., 1387 Stechschulte, Daniel J., 970 Steinberg, Alfred D., 9, 285 Steiner, Joan, 1884 Stephcns, Christopher G., 1955 Stevens, David A., 728 Stitzel, Ann E., 56 Stobo, Jack, 1589 Stoner, Richard D., 804, 1961, 2154 Storb, RMner, 1508 Strober, Samuel, 520 Strunk, Robert, 905 Suhrbier, Katherine M., 1467 Suszko, lrena M., 1855 Swanborg, Robert H., 594 Swierkosz, James E., 594

Tada, Tomio, 783 Talal, Norman, 326 Tamerius, John D., 1987 Tanapatchaiyapong, Prasert, 2068 Terasaki, Paul I., 1124, 2063 Terres, Geronimo, 804 Terry, William D., 1426 Thobie, Nicole, 427 Thoman, Marilyn, 1873 Thomas, David W., 1602 Thomas, E. Donnall, 1508 Tignor, Gregory H., 260 Tingle, Aubrey J., 716 Tishon, Antoinette, 370 Tokuda, Sei, 1660 Tomasi, Thomas B., Jr., 162, 320, 488, 2274 Tomazic, Vesna, 965

Toni, Robert, 1250 Trenkner, Ekkhart, 1873 Twomey, Jeremiah J., 2278 Tung, Kenneth S. K., 186

Ulevitch, Richard J., 1383 Unanue, Emil R., 293, 1804 Underdown, Brian J., 949

v. Boehmer, Harald, 70 Vaerman, Jean-Pierre, 1035 Valet, Gunter, 339, 1667 van Boxel, John A., 398 Vann, Douglas C., 1149 Varga, Janos M., 1565 Vaz, Nelson M., 1369 Vicari, Giuseppe, 1061 Villanueva, Valentine R., 852 Volanakis, John E., 2135

Waksman, Byron H., 215, 260 Waldman, Robert H., 1322 Waldron, James A., Jr., 746 Ward, P. A., 1 Ward, Peter A, 858 Warren, Kenneth S., 222, 996 Warren, Robert W., 2202 Wasserman, Stephen I., 351 Watkins, A. C., 1415 Watson, James, 1873 Weiden, Paul L., 1508 Werblin, Theodore P., 2002 Westaway, E. G., 656 Whalen, John J., 1488 White, Stuart C., 178 Wick, Georg, 444 Wiktor, Tadeusz J., 2013 Williams, Ralph C., Jr., 1955 Wilson, Curtis B., 241 Winkelstein, Jerry A., 1635 Wistar, Richard, 1949 Wolf, Benjamin, 1782 Wolfenstein-Todel, Carlota, 871 Wolff, Sheldon M., 737 Wong, A. K. C., 2251 Wood, David D., 1181 Woodruff, Jack F., 2176 Woodruff, Judith J., 2176 Woods, Roy, 633 Wortis, Henry H., 468 Wright, P. W., 1267 Wyman, Susanne, 1164

Yagi, Mary Jane, 693 Yoshida, Takeshi, 1540 Younmns, Anne S., 271 Youmans, Guy P., 271

1974] INDEX 2291

Yu, Alice, 1285, 1296 Yurchak, Anthony M., 488 Yutoku, Masamichi, 911, 1774

Zatz, Marion M., 101 Ziff, Morris, 1494

Zighelboim, Jacob, 433 Zimmermun, Barry, 249 Zinkernagel, Rolf M., 496, 1548 Zolla, Susan, 2068 Zucker, Marjorie B., 1219 Zucker-Franklin, Dorothea, 234

S U B J E C T I N D E X

Acid lability, of rhinoviruses, 919 pH, IgE dissociation from basophit receptors at,

1078 ribonucleic, see RNA

Activation basophil, by concanavalin A, 2117 lymphocyte, biologic expressions of, 1360

Adenovirus, type-specific anti-hemagglutinin sera, counterimmunoelectrophoresis with, 987

Affinity antibody-binding

distribution, 2002 immune response and, 1255, 2227

chromatography, purification of detergent- solubilized HL-A antigens by, with hemagglutinin from L e n s c u l i n a r i s , 1190

Agglutinating factor, macrophage receptors for, 1867

Aggregation, induced in human blood platelets by zymosan, 1219

Aging antibody-forming capacity and, 1467 effect on lymphocyte response in mixed leuko-

cyte culture, to phytoheInagglutinin, and in the graft-vs-host reaction, 1194

homogeneous immunoglobulins in sera of mice during, 2271

lymphopoietic potential of bone marrow cells and, 1244

related decline in suppressor T cell function, 9 Allelic selection of light chain allotypes, 601 Allergic contact dermatitis, lymphokines in, 1488 Alloantibody-producing cells, plaque assay for

detecting, 2251 Altoantigen

immune stimulation of protein synthesis in cells responding to, 47

Ly-alloantigen, antibodies specific for, 683 solubilized, blocking activity induced by, 433 0-alloantigen, antibodies specific for, 683

Allogeneic effect, increased cellular immune and inflammatory responses, 2166

Allografts, tooth bud, orthotopic, cytotoxic antibodies and lymphocytes induced by, 776

Alloimmunity, against teeth, 776 Allotype

at a-chain locus, 1035 light chain, allelic selection of, 601 secretory IgA, 877

Amino terminal sequences, of light and heavy chains, 941

Ammonium sulfate precipitation, determination of soluble immune complex molar composi-

2292

tion and antibody association constants by, 451

AMP, cyclic, histamine release and, 511,664 Analysis, dilution, limiting with cellular coopera-

tion and soluble factors, 1149 Anamnestic response, see Response, anamnestic Anaphylaxis

cutaneous, susceptibility to, 1369 eosinophil, chemotactic factor of, 351 slow reacting substance, release from leuko*

cytes, 897 Antibody

against brain blood vessels, adsorption properties, 607

alloantibody, see Alloantibody anti-DNP, 19S and 7S, increased binding affinity

during immune response, 2227 -antigen complexes

carrier-specific enhancement of immune response using, 804

complement interaction with, 830 -antigen reactions, quantitation by radioim-

munoassay, 1008 anti-host, in graft-vs-host reaction, 410 anti-KLH, effect of irradiation and cyclopbos-

phamide on formation of, 564 anti-phosphorylcholine, idiotypic specificity

and binding characteristics, 1747 anti-0, abrogation of macrophage migration

inhibition by, 1741 association constants, determination of soluble

immune complex molar composition and, 451 autoantibody, see Autoantibody -binding affinity-

distribution, 2002 immune response and, 1255, 2227

C3-independent, immunosuppressive activity of anti-lymphocyte serum in C3-deficient alice mediated by, 858

cytotoxic complement-dependent, to Moloney sarcoma

cells, 1987 induced by orthotopic tooth bud allografts,

776 -dependent cell cytotoxicity

complement in, 398 enzyme effects on, 26 in lymphoid organs, 37 in prospective kidney transplant recipients,

89O -forming

capacity, decline and restoration, 1467 cell precursors, in adherent spleen cells, 430

1974] INDEX 2293

cells, reaginic, in spleen and bone marrow of immunized mice, 1609

system, at advanced stages of the secondary response to tetanus toxoid, cellular bases for relative radioresistance of, 2154

hemolytic, production rate by single cells, 17 quantitative radioisotopic assay for, 756

hepatitis B antigen subtype, passive hemagglutination assay for, 1100

homocytotropic, regulation of formation, 783 IgA, response to Type I I I pneumococcal poly-

saccharide, regulation of, 1042 IgG

response to Type II1 pneumococcal polysaccharide, regulation of, 1042

specificity, after challenge with antigenically related togaviruses, 656

IgM rate of release from MOPC 104E plasmacy-

toma, 266 sites, 2227, 2235 specificity, after challenge with antigenically

related togaviruses, 656 -infectious vaccinia virus complexes, interaction

of rheumatoid factor with, 2087 interaction with cytotoxic effector cells in im-

mune or nonimmune spleen cells, 2219 -mediated target cell lysis by nonimmune cells,

792 phage neutralizing, induction of myeloma and

lymphoma cell cultures to produce, 1415 production, non-H~24inked genes and, 1329 red blood cell, having limited heterogeneity,

isolation and characterization, 1337 release, from tumor cells, 266 response, see Response, antibody 7S

anaphylactic, characterization and properties, 722

anti-DNP, increased binding affinity during immune responses, 2227

19S, anti-DNP, increased binding affinity during immune response, 2227

secretion, discontinuous, during secondary response to erythrocytes, 1602

specific for 8- and Ly-alloantigens in antisera, 683

structure, 941 synthesis, control of, 1255 thymocytotoxic, immunofluorescence studies on,

285 to B cells, 462

Antigen alloantigen, see Alloantigen allotypic, complement-dependent precipitation,

830 -antibody complexes

carrier-specific enhancement of immune response using, 804

complement interaction with, 830 -antibody reactions, quantitation by radioim-

munoassay, 1008 Australia, reduced and alkylated, antigenicity

of, 416 bifunctional, immune response to, 883 -binding cells

antigen-reactive lymphocyte dissociation from in a T lymphocyte enriched population, 1085

B cells, 1726, 1734 DNP-specific, ontogeny, 2202 T cells, 293, 1726, 1734

cellular, specific antisera effect on the metabolism of, 1285, 1296

circulating, in schistosomiasis, 1500 contaminant, in commercial horseradish peroxi-

dase, 1094 cytomegalovirus-specific membrane, 1680 determinant, on plasmacytes, 911 E, ragweed, polymerized, 1855 Echinococcus granulosus, cyst membrane, with

blood group P1 activity, 1061 epidermal cell, 311 fetal, tumor-associated, host response to, 1026 glutaraldehyde-treated, effect on migration

inhibition factor, 1578 H-2

anti-H-2 sera, inhibition of antigen binding to T and B cells by, 1734

inhibition of cell-mediated cytolysis by, 926 soluble, immunogenicity and partial purifica-

tion of, 1643 hepatitis B, subtype antibody, passive hemag-

glutination assay for, 1100 histocompatibility, phytohemagglutinin effect

on, 852 HL-A

detergent-solubilized, purification by affinity chromatography with hemagglutinin from Lens culinaris, 1190

purification from normal serum, 1124 I, purification of glycoproteins with different I

determinants from hyatid cyst fluid and from human milk on insoluble anti-I immunoadsorbents, 145

IgG marker, detected by 19S anti-IgG in streptococcal antisera, 627

-induced lymphocyte proliferation, 746, 1705 lymphotoxin, 1347 mediator release from mast cells, phospho-

tidylserine enhancement of, 970 macrophage-associated, 746, 1804 membrane, blocking of cell-mediated cytolysis,

926

2294 INDEX [VOL. 112

non-viral, lactic dehydrogenase virus infection and immune response to, 370

plasma membrane constituent on thymus cells, 249

plasmacyte-thymocyte, 1774 polyribitol-phosphate, cross-reaction with cap-

sular polysaccharide of Haemophilus in- fiuey~zae type B, 649

purified protein derivative of tuberculin and, 151 -reactive lymphocytes, dissociation from anti-

gen-binding cells in a T lymphocyte enriched population, 1085

-related togaviruses, specificity of IgM and IgG antibodies after challenge with, 656

rhinovirus, acid lability, 919 sensitivity, of immune T lymphocytes, macro-

phage control of time-dependent changes in, 359

soluble, cytotoxic immune cells specific for, 2219 -specific inhibitory T cell factor in hapten-

specific homocytotropic antibody response, 783

suppression of phytohemagglutinin responses, 215

surface, thymus, 249 thymocyte-plasmacyte, 1774 thymus leukemia

isolation, 1285 synthesis and degradation in presence of

thymus leukemia antiserum, 1296 Antigenicity, of reduced and alkylated Australia

antigen, 416 Antiserum, see Serum, antiserum Assay, see also Electroimmunoassay; Radioim-

mun oassay immune reactivity, stimulation of early protein

synthesis as, 47 lymphotoxin, human, 2111 passive hemagglutination, for hepatitis B anti-

gen subtype antibody, 1100 plaque

for detecting alloantibody-producing cells, 2251

hemolytic, micro-technique for, 1271 -rosette, 1782

protein synthesis, semimicro, detection of lymphocyte stimulation and mixed lymphocyte interaction with, 1426

radioisotopic, quantitative, for hemolytic antibody, 756

rosette-plaque, 1782 serum bactericidal activity, release of s~Cr-endo-

toxin from bacteria as, 2184 serum factor, enhancement and antagonism of

spleen cell activity in vitro in mammary neoplasia detected by, 439

ATP, histamine release and, 664

Australia antigen, reduced and alkylated, antigenicity of, 416

Autoantibody detected by lysis of lymphoma cells, 320 epidermal, natural and acquired, 2063 to tubular and glomerular basement membranes,

241

Babesiosis, renal complications, 1 Bacteria, 5zCr-endotoxin release from, as an assay

of serum bactericidal activity, 2184 Basement membrane, renal, autoantibodies to, 241 Basophil

activation by concanavalin A, 2117 receptors, IgE dissociation from at acid pH, 1078 turn off, by excess bridging, 1762

Bat virus, Lagos, infection with, 260 Binding

al-anti t rypsin to IgA, 2274 antibody, see Antibody, binding affinity antigen, thymic lymphocytes, 293 complement, without lysis, 866 energies, gastrin system, 1008 erythrocyte, inhibition by eytochalasin B, 862 functions, multiple, immunogtobulins with, 1565 hapten, protein 460 region of, 96 IgE, with mast cells, 1652 menadione, sulfhydryl-containing heavy chain

peptide of protein 460 affecting, 96 Biologic expressions, of lymphocyte activation,

1360 Biosynthesis, complement, inhibition in vitro by

chemical carcinogens, 1107 Blockade receptor, by tolerogen, 1793 Blocking

of cell-mediated cytolysis, 926, 1308 serum factors associated with IgG, 1267 solubilized alloantigen induction of, 433

Blood cell, red

antibody with limited heterogeneity, isolation and characterization of, 1337

E rosette formation after neuraminidase treatment of, 1628

heterologous, purified protein derivative of tuberculin effect on immune response to, 151

groups immunochemical studies on, 145 P1, active carbohydrate antigen of Echinococ-

cus granulosus cyst membrane, 1061 normal, percentage of monocytes among mono-

nuclear cell fractions from, 234 peripheral lymphocytes

enumeration of B lymphocytes by rosette method for detecting surface-bound immunoglobulin, 1494

1974] INDEX 2295

E rosette formation after neuraminidase treatment of, 1628

thymus-derived lymphocyte identification and quantitation, 520

transfusions, prior, effect on marrow grafts, 1508 vessels, brain, adsorption properties i~,, vitro and

in vivo of antibodies raised against, 607 Bone marrow cells, 836

from aged mice, lymphopoietic potential, 1244 in resistance to Listeria monocytogenes, 1407 reaginic antibody-forming, 1609 T cells, 836, 960

Brain, blood vessels, adsorption properties in vitro and i~ vivo of antibodies raised against, 607

BrdU, effect on lymphocyte proliferation, 1705 Bridging, excess, basophil turn off by, 1762 Bronchus-associated lymphoid tissue, prolifera-

tive response after local and systemic immunization, 1997

Brucellin, T lymphocytes in the primary humoral antibody response to, 716

Brucellosis, polyadenine:polyuridine effect on, 1535

Carbohydrate antigen, of Echinococcus granulosus, with blood group P~ activity, 1061

Carboxy-terminal deletion, IgA1 myeloma protein with, 1517

Carcinogens, chemical, inhibition of C2 and C4 biosynthesis by, 1107

Carrier cross-stimulation in vitro, 1354 cross-tolerance in vivo, 1354 function in immune deviation, 1264 -specific cells, multiplicity of soluble factors

released from, 1685 -specific enhancement, of immune response using

antigen-antibody complexes, 804 thymus-independent, IgM anamnestic immune

response to haptenic determinant DNP on, 427

Cell(s), see also Leukocyte; Lymphocyte; Lym- phoid

adherent, cell cooperation and, 1873 alloantibody-producing, plaque assay for detect-

ing, 2251 allogeneic, reactivity elevation in fetal thymo-

cytes, 305 antibody-forming

precursors in adherent spleen cells, 430 reaginie, in spleen and bone marrow of im-

munized mice, 1609 antigen -binding

antigen-reactive lymphocyte dissociation from in a T lymphocyte enriched population, 1085

DNP-specific, ontogeny, 2202

antigens, specific antisera effect on the metabolism of, 1285, 1296

antLplasma, effect of serum on B cells, 462 B cells

antibodies to, 462 anti-plasma cell serum effect on, 462 complement receptors, immunoglobulin and,

1931 from aged mice, lymphopoietic potential, 1244 immune stimulation of protein synthesis in, 47 in resistance to Listeria ~wnocytoge~es, 1407 lymphoid, delineation of, 444 purification of, 420 -T cell collaboration between species, 1613 tolerance induction in, 1891

blood, red antibody, with limited heterogeneity, isola-

tion and characterization, 1337 E rosette formation after neuraminidase treat-

ment of, 1628 heterologous, purified protein derivative of

tuberculin effect on immune response to, 151 bound C4, immunochemical quantitation, 979 carrier-specific, multiplicity of soluble factors

released from, 1685 collaboration, in anamnestic response, 583 cooperation

adherent cells and, 1873 in antibody responses, 1149

effector anti-immunoglobulin to distinguish, 792 cytotoxic, in immune or nonimmune spleen

cells, antibody interaction with, 2219 diversity, in cellular immune response to sar-

coma virus-induced tumors, 1477 epidermal, antigens, 311 epithelial

~2-microglobulin production by, 137 secretory, differential localization of free and

bound secretory component, 1553 exudate, immune, abrogation of macrophage

migration inhibition by pretreatment with anti-O antibody and complement, 1741

fractions, mononuclear, in normal blood, percentage of monocytes among, 234

hematopoietic, ~2-microglobulin production by, 137

immune, cytotoxic, specific for defined soluble antigens, 2219

immunoglobulin-containing, ontogeny, 555 interactions, between histoincompatible T and

B lymphocytes, 855 lymph node

antiserum and, production of augmented experimental autoimmune thyroiditis lesions by combined transfer of, 478

2296 INDEX [vob. 112

hapten-primed, specificity differences among, 1782

in vitro anamnestic response of, 583 lymphoid

B and T, delineation of, 444 C3 receptors on, 1766 cytotoxicity, antibody-dependent, comple-

ment in, 398 immune, synergistic cooperation between iso-

antiserum and, 2102 line, migration inhibitory factor produced by,

675 required for interferon production after mito-

gen stimulation, 1589 separation, 1231

lymphoma autoantibodies detected by lysis of, 320 induction to produce specific phage neutraliz-

ing antibody, 1415 mast

activation by low molecular weight stimuli, 573

cyclic AMP content and histamine release in, 511, 664

IgE binding with, 1652 phosphotidylserine enhancement of antigen-

induced mediator release from, 970 -mediated cytolysis, 926, 1308 -mediated cytotoxicity, 26, 37,398, 890, 996 -mediated immunity, 926, 1308, 1322, 1826 mesenchymal, fl~-microglobulin production by,

137 mononuclear, infiltrating the minor salivary

gland in SjSgren's syndrome, 641 myeloma, induction to produce specific phage

neutralizing antibody, 1415 nonimmune, antibody-mediated target cell

lysis by, 792 plaque-forming, response, see Response, plaque-

forming cell plasma, malignant, interferon production by,

from patients with multiple myeloma, 1131 proliferation, as index of immune competence,

436, 869 regulatory, in development of IgG and IgA

antibody response to Type I I [ pneumococcal polysaccharide, 1042

sarcoma, Moloney, complement-dependent cytotoxic antibodies to, 1987

single, hemolytic antibody production rate by, 17

spleen activity in mammary neoplasia, 439, 693 adherent, antibody-forming cell precursors

in, 430 antiviral activity in experimental Venezuelan

equine encephalomyelitis infection, 1070

eoneanavalin A-activated, suppression of plaque-forming cell responses in vitro by supernatant fluids from, 1360

cultured, immune response to erythrocytes, 326

endotoxin-stimulated, 770 immune or nonimmune, antibody interaction

with cytotoxic effector cells in, 2219 incubation, reversal of tumor-mediated sup-

pression of immune reactivity by, 1900 proliferation inhibitory factor production by,

1435 stem, hematopoietic, anti-thymocyte serum in-

teraction with, 822 stimulation, detection of tolerance and contact

sensitivity to DNFB by, 115 suppressor, age-related functional decline, 9 T cell

antigenic plasma membrane constituent on, 249

-B cell collaboration between species, 1613 bone marrow, 960 factor, inhibitory, antigen-specific, in hapten-

specific homocytotropic antibody response, 783

immune, in mice with regressing tumors, 1815 immune stimulation of protein synthesis in,

47 interferon, in immunodeficiency, 617 lymphocyte trapping and, 101 lymphoid, delineation of, 444 PHA-responsive, thymidine suicide of, 333 purification of, 420 splenic, immunoregulatory role of, 546 suppressor, 9,404, 2020

target, tysis, antibody-mediated, by nonimmune cells, 792

tolerant, receptor blockade by tolerogen, 1793 tumor, antibody release from, 266

Cellular basis

for immunity, 107 for immunodepression in mice with plasma-

cytomas, 2068 for relative radioresistance of the antibody-

forming system at advanced stages of the secondary response to tetanus toxoid, 2154

for tolerance or immunity, 107 events, in tolerance, 1354 immunity

in Chagas disease, 1578 in graft-vs-host reaction, 706 increased, allogeneic effect, 2166 induction to herpes simplex virus, 1019

immunoadsorbents, 1231 requirements, for antibody synthesis induction

1974] INDEX 2297

by solubilized T2 phage and immunogenic RNA, 1981

Cellulose, DEAE, see DEAE cellulose Chagas disease, see Disease, Chagas Chain (s)

a-chain, locus, allotype at, 1035 heavy

amino terminal sequences of, 941 IgA, 1605, 1623 IgG~ ~ and IgAl k myeloma proteins, variable

regions, 871 J chain, 1401

Fc region of lgM and, 229 isolation and molecular weight studies, 162

light allotypes, allelic selection of, 601 amino terminal sequences of, 941 IgG2 X and IgA1 ~ myeloma proteins, simi-

larities in a single patient, 871 variable region, sequence restriction in, 633

Chemotactic factors, ability to induce lysosomal enzyme release, 2047, 2055

Chlamydial infection, in patients with lymphogranuloma venereum and urethritis, fluorescent antibody responses to, 2126

Cholera toxin, suppression of cell-mediated and foreign body inflammatory responses, 996

Choleragen, immunity to, 1452 Choline phosphatides, complement consumption

associated with reaction of C-reactive protein with, 2135

Cholinergic stimulation, of phagocytic enzyme release, 210

Choriomeningitis, lymphocytic, cytotoxic thymus-derived lymphocytes in, 1548

Chromatography affinity, purification of detergent-solubilized

HL-A antigens by, with hemagglutinin from Lens cu l i ,mr is , 1190

DEAE cellulose, fractionation of sera by, 1267 Chronic granulomatous disease, see Disease,

chronic granulomatous Cbymopapain C, effect on primary and secondary

immune response, 1660 Coccidiodin, tolerance induction to, 387 Colony-stimulating factor, production in mito-

gen-stimulated lymphocyte cultures, 502 Competence, immune, cellular proliferation as

index of, 436, 869 Complement

allotypic antigen-dependent, precipitation, 830 antibody-dependent lymphoid cell-mediated

cytotoxicity and, 398 binding, without lysis, 866 C1

enzyme activity, kinetics of, 905

interaction with lipopolysaccharides and Lipid-A, 935

Clq, enzymatic digestion, 2094 Clr proenzyme, isolation and characterization,

1667 Cls proenzyme, isolation and characterization,

339 C2

biosynthesis inhibition by chemical carcinogens, 1107

interaction with lipopolysaccharides and Lipid-A, 935

C3 antigenic properties, 1444 -deficient mice, immunosuppressive effects

of anti-lymphocyte serum in, 858 receptors, 770, 1766

C3b, kinetics of properdin system enzymes con- trolled by, 1115

C4 biosynthesis inhibition by chemical carcino-

gens, 1107 cell bound, immunochemical quantitation of,

979 interaction with lipopolysaccharides and

Lipid-A, 935 renal cortical tubulointerstitial disease in

absence of, 1387 C5, dysfunction, 1164 components, terminal, failure to induce lysis of

Moloney virus transformed lymphocytes, 866

C-reactive protein complex interaction with, 2094

-dependent and -independent platelet reactions to im-

munologic stimuli, 1201 cytotoxic antibodies to Moloney sarcoma

cells, 1987 damage, Forssman-containing liposomes, 1949

fixation test, antisera to cytomegaloviruses used in, 528

pathway alternate, 56, 763, 2260 classic, 763, 2260

receptors B cell, immunoglobulin and, 1931 C3,770, 1766

Concanavalin A -activated spleen cell cultures, suppression of

plaque-forming cell responses in vitro by supernatant fluids from, 1360

basophil activation by, 2117 bone marrow T cell response to, 960 immunosuppression in vivo, 63

Contact sensitivity, to DNFB, 115, 849 Control, genetic, of immune response, 1329


Counterimmunoelectrophoresis, with adenovirus type-specific anti-hemagglutinin sera as a rapid diagnostic method, 987

Cryptococcus neoformans infection, classic and alternate complement pathway rolls in host defenses against, 2260

Cultures leukocyte, mixed, age effect on lymphocyte re-

sponse in, 1194 lymphocyte, mitogen-stimulated, colony-stimu-

lating factor production in, 502 Curve, dose-response, inhibitory region, 1762 Cutaneous anaphylaxis, susceptibility to, 1369 Cyclophosphamide

anti-KLH antibody formation and, 564 -pretreated lymphocytes, 1594

Cyst membrane, Echi~wcoccus granulo~us, blood PI active carbohydrate antigen of, 1061

Cytochalasin B, erythrocyte binding inhibited by, 862

Cytolysis, cell-mediated, blocking of, 926, 1308 Cytomegalovirus (es)

antisera to, use in immunofluorescence and complement fixation tests, 528

-specific membrane antigen, 1680 Cytotoxic

antibodies, complement-dependent, to Moloney sarcoma cells, 1987

effector cells, in immune or nonimmune spleen cells, antibody interaction with, 2219

immune cells, specific for defined soluble antigens, 2219

Cytotoxicity, cell-mediated complement in, 398 depression after Friend leukemia virus infection,

2077 enzyme effects on, 26 in lymphoid organs, 37 in prospective kidney transplant recipients, 890

DEAE cellulose chromatography, fractionation of sera by, 1267

Defect, opsonic, familial, C5 abnormality in, 1164 Defenses, host, against Cryptococcus ,~eoformans

infection, classic and alternate complement pathway rolls in, 2260

Degradation, thymus leukemia antigens in presence of thymus leukemia antiserum, 1296

Dermatitis, allergic contact, lymphokines in, 1488 Detergent-solubilized HL-A antigens, purification

by a~finity chromatography with hemagglutinin from Lefts culi~taris, 1190

Deviation, immune, carrier function in, 1264 Dilution analysis, limiting with cellular coopera*

tion and soluble factors, 1149 Dinitrobenzene compounds (DNFB), sensitivity

to, 115, 849

Dinitrochlorobenzene-sensitive leukocyte cultures, blastogenesis of autologous, allogeneic, and syngeneic lymphocytes in response to lymphokines generated in, 1488

Disease Chagas, cellular immunity in, 1578 chronic granulomatous, exocytosis of neutrophil

granule enzymes in, 1383 immunodeficiency, T lymphocyte effector func-

tion in, 617 renal cortical tubulointerstitial, in absence of

C4, 1387 Divalent haptens, histamine release from leuko-

cytes and, 1757 DNFB, see Dinitrobenzene compounds DNP

anti-DNP antibodies, 19S and 7S, increased binding affinity during immune response, 2227

B cells, tolerance in, 1158 on thymus-independent carrier, IgM anam-

nestic immune response to, 427 -specific antigen-binding cells, ontogeny, 2202

Dose-response curve, inhibitory region, 1762 Drugs, antischistosomal, as anti-inflammatory

agents, 222

Ear middle, secretory ~/A and, 488 swelling, detection of tolerance and contact

sensitivity to DNFB by, 115 Echinococcus granulosus, cyst membrane, blood P1

active carbohydrate antigen of, 1061 Effector

cell, see Cell, effector T lymphocyte, function in immunodeficiency

diseases, 617 Egg, schistosome, granuloma, suppression of, 222 Electroimmunoassay of IgM, 1420 Embryos, acquired immunity in, 2148 Emetic, tartar, anti-inflammatory effects of, 222 Encephalomyelitis, experimental

allergic species variabili ty of, 594 treatment with hornologous myelin basic

protein, 392 Venezuelan equine infection, antiviral activity

of immune spleen cells in, 1070 Endotoxin

classic and alternate complement pathway activation by, 763

~lCr-, release from bacteria as an assay of serum bactericidal activity, 2184

-induced infection, role of iron in nonspecific resistance to, 737

-stimulated spleen cells, 770 Energies, binding, gastrin system, 1008

1974] INDEX 2299

Enzymatic digestion of Clq, 2094 Enzyme

activity, C1,905 effects on cell-mediated cytotoxicity and anti-

body-dependent cell cytotoxicity, 26 granule, in chronic granulomatous disease neu-

trophils, exocytosis of, 1383 properdin system, kinetics, C3b control of, 1115 release

lysosomal, induction by chemotactic factors, 2047, 2055

phagocytic, cholinergic stimulation of, 210 Eosinophil, chemotactic, factor, of anaphylaxis,

351 Epidermal

autoantibodies, natural and acquired, 2063 cell antigens, 311

Erythrocytes, e'ee a l s o Cells, blood, red binding, inhibition by cytochalasin B, 862 discontinuous antibody secretion during second-

ary response to, 16)02 immune response of cultured spleen cells to, 326 T lymphocyte receptors for, 862 technetium-99m-labeled, hemolysis of, 756

Esterases, maerophage-associated, enhancement of migration inhibition factor by inhibition of, 1571

Exocytosis, neutrophil granule enzymes, in chronic granulomatous disease neutrophils, 1383

Expression, T cell-mediated immunity, 1308

Factor leukocyte inhibitory, see Leukocyte1 inhibitory

factor migration inhibitory, see Migration, inhibitory

factor soluble, in antibody responses, 1149

(Fc)~ fragment, subfragments from, 1920 Fetus

antigens, tumor-associated, host response to, 1026

life, IgA production during, 1605 thymocytes, elevation of reactivity to allo-

geneic cells and phytohemagglutinin in, 305 Fixation, complement, test, see Complement,

fixation test; Test, complement fixation Foreign body inflammatory response, cholera

toxin suppression of, 996 Forssman-containing liposomes, complement-de-

pendent damage due to interaction with a monoclonal IgM, 1949

Fractions, cell, mononuclear, in normal blood, percentage of monocytes among, 234

Fractionation, serum, by DEAE cellulose chromatography, 1267

Friend leukemia virus

anti-~ specific immunosuppression effect on, 1698

depression of T cell-mediated cytotoxicity after infection with, 2077

GALT, immunoglobulins and, 555 Gastrin system, radioimmunoassay quantitation

of antigen-antibody reactions in, 1008 Genes, non-H-2-1inked, antibody production and,

1329 Genetic control

of allotypes of secretory IgA, 877 of immune response, 1329

Germinal center, proliferation patterns in lymph nodes after primary and secondary stimulation with tetanus toxoid, 1961

Glands, salivary, mononuclear cell infiltration in Sj6gren's syndrome, 641

Globulin, see a l so Imnmnoglobulin; Microglobulin ~,-globulin, cellular basis for tolerance or im-

munity to, 107 Glomerulonephritis, in graft-vs-host reaction, 410 Glomerulus, renal, immune complex during nor-

mal pregnancy, 186 Glutaraldehyde-treated specific antigen, effect on

migration inhibition factor, 1578 Gtycopeptides, heavy chain, from IgA myeloma

protein, 1623 Glycoprotein

immunogen, non-peroxidase, in commercial horseradish peroxidase, 1094

purification with different I determinants from hydatid cyst fluid and from human milk on insoluble anti-I immunoadsorbents, 145

GMP, cyclic, stimulation of phagocytic release of neutral protease from neutrophils by, 210

Grafts marrow

abrogation of sensitization by procarbazine and antithymocyte serum, 1508

effect of prior blood transfusions on, 1508 -vs-host reaction

age effect on lymphocyte response in, 1194 anti-host antibodies in, 410 cellular immunity in, 706 glomerulonephritis in, 410

Granuloma, schistosome egg, suppression of, 222 3',5'-Guanosine monophosphate, see GMP Gut-associated tymphoepithelial tissues, im-

munoglobulins and, 555

H-2 antigen, inhibition of cell-mediated cytolysis

by, 926 anti-H-2 serum, inhibition of antigen binding to

T and B cells by, 1734

2300 INDEX [voL 112

soluble, immunogenicity and partial purification, 1643

Haemophilus influenzae, type B, polyribitol-phosphate cross-reaction with capsular polysaccharide of, 649

tIapten -binding region of protein 96, 460 determinant (DNP) on thymus-independent

carrier, IgM anamnestic immune response to, 427

divalent, histamine release from leukocytes and, 1757

-primed lymph node cells, specificity differences among, 1782

-specific antibody response, homocytotropic, antigen-

specific inhibitory T cell factor in, 783 delayed hypersensitivity, roll of lipid in in-

duction of, 1526 Heat-labile opsonins, staphylococcal protein A

and, 1177 Hemagglutination assay, passive, for hepatitis B

antigen subtype antibody, 1100 Hemagglutinin

anti-hemagglutinin sera, adenovirus type- specific, counteriramunoelec trophoresis with, 987

Lens culinaris, purification of detergent-solubilized HL-A antigens by affinity chromatography with, 1190

Hemolysin, antibody production, by single cells, rate of, 17

Hemolysis of technetium-99m:labeled erythrocytes, 756

Hemolytic plaque assay, micro-technique for, 1271 Hepatitis B antigen, subtype antibody, passive

hemagglutination assay for, 1100 Herpes simplex virus infection

cellular immunity to, 1019 humoral immunity to, 1019 lymphocyte interferon production and trans-

formation after, 728 Histamine release

ATP and, 664 cyclic AMP and, 511,664 from leukocytes, divalent requirement, 1757 inhibitory region of dose-response curve, 1762

Histocompatibility antigens, phytohemagglutinin effect on, 852

Histoincompatibility, cell interactions between histoincompatible T and B lymphocytes, 855

HL-A antigens detergent-solubilized, purification by affinity

chromatography with hemagglutinin from Lens culinaris, 1190

purification from normal serum, 1124

Horseradish peroxidase, commercial, potent non- peroxidase glycoprotein immunogen in, 1094

Host defenses, against Cryplococcus neoformans in-

fection, classic and alternate complement pathway roles in, 2260

response, to tumor-associated fetal antigens, 1026

Hydatidosis, solid phase radioimmunoassay for diagnosis of, 1674

Hydrolysis, tryptic, of IgM at elevated tempera- ture, aggregation of Fc'~ subfragments produced by, 1920

Hydroxylamine, effect on immune response to mycobacterial ribonucleic acid vaccines, 271

Hypergammaglobulinemia, induction with xenogeneic tumors, 2241

Hypersensitivity, delayed hapten-specific, role of lipid in induction of,

1526 to trachoma. 540

Immune competence, cellular proliferation as index of,

436, 869 complexes

in Mycoplasma pneumoniae infection, 413 in renal glomerulus during normal pregnancy,

186 soluble, saturation of reticuloendothelial

system with, 1939 deviation, carrier function in, 1264 reactivity, bee Reactivity, immune response, see Response, immune stimulation-inhibition of spontaneous tumors

of various histologic types, 1051 Immunity

acquired, in embryos, 2148 alloimmunity, against teeth, 776 cell-mediated, 926

highly sensitive assay for human lymphotoxin, 2111

induction and expression, 1308 suppression by cells from progressor animals,

1826 to Mycobacterium tuberculosis, 1322

cellular, 107 in Chagas disease, 1578 in graft-vs-host reaction, 706 increased, allogeneic effect, 2166 to herpes simplex virus, 1019

humoral, to herpes simplex virus, 1019 RNA, metabolic inhibitors and, 271 to purified bacterial toxin (choleragen) and

toxoid, 1452

1974] 1NDEX 2301

to sarcoma virus-induced tumors, 1815, 1826 tumor

lactic dehydrogenase virus infection and, 1560

Immunoadsorbents, cellular, 1231 Immunodeficiency

diseases, T lymphocyte effector function in, 617 membrane receptors and lymphocyte respon-

siveness in, 376 T cell interferon in, 617

Immunodepression, cellular basis in mice with plasmacytomas, 2068

Immunoelectrophoresis, crossed, of IgM, 1420 Immunoferritin studies, of ~2-microglobulin dis-

tribution and mobility on lymphocyte membrane, 2036

Immunofluorescence study of ~2-microglobulin distribution and

mobility on lymphocyte membrane, 2036 study of thymocytotoxic antibody, 285 test, antisera to cytomegaloviruses used in, 528

Immunogen, glycoprotein, non-peroxidase, in commercial horseradish peroxidase, 1094

]mmunoglobulin, see also Allotype; Globulin anti-immunoglobulin

effector cell populations distinguished by, 792 inhibition of antigen binding to T and B cells

by, 1734 -bearing lymphocytes, ontogeny, 2202 chain, see Chain components, mucosal and glandular distribu-

tion, 1553 -containing cells, ontogeny, 555 GALT and, 555 ~,A, secretory, middle ear and, 488 homogeneous, in sera of aging mice, 2271 IgA

al-ant i t rypsin binding to, 2274 deficiency, T lymphocyte effector function

abnormality in mitogen-stimulated interferon in patients with, 617

immune response to TNP determinant group, 812

monoclonal proteins derived from single patient, 201

myeloma proteins, glycopeptides of heavy chains from, 1623

production during fetal life, 1605 resistance to proteolysis, 949 secretory, allotypes of, 877

IgAl myeloma proteins light chains and variable regions of heavy

chains of, 871 with carboxy-terminal deletion, 1517

IgD, on lymphocyte surface from patients with chronic lymphatic leukemia, 1952

IgE

binding with mast cells, 1652 dissociation from basophil receptors at acid

pH, 1078 isolation from reaginic rat serum, 1909

IgG antibody specificity after challenge with anti-

genically related togaviruses, 656 antigenic marker, detected by 19S anti-IgG in

streptococcal antisera, 627 Fc, pneumococci and, 1955 hybrid IgG4-IgG2, 1277 monoclonal proteins, 201 serum blocking factors associated with, 1267

IgG2 myeloma proteins, light chains and variable regions of heavy chains of, 871

IgM aggregation of Fcl~ subfragments produced

by tryptic hydrolysis of, 1920 anamnestic immune response to the haptenic

determinant DNP on a thymus-independent carrier, 427

antibody sites, 2227, 2235 antibody, specificity after challenge with

antigenically related togaviruses, 656 crossed immunoelectrophoresis and electro-

immunoassay of, 1420 Fv fragment, 1373 immune response to TNP determinant group,

812 increased binding affinity of 19S and 7S anti-

DNP antibodies during immune response, 2227

J chain and Fc region of, 229 monoclonal, complement-dependent damage

of Forssman-containing liposomes due to interaction with, 1949

rate of release from MOPC 104E plasmacytoma, 266

response, kinetics of priming for, 1582 in interaction of pneumococci and properdin

pathway, 1635 multiple binding functions, 1565 production, in endotoxin-stimtflated spleen

cells, 770 receptors, in lymphoid organs, 37 relationship to B cell complement receptors,

1931 surface-bound, enumeration of B lymphocytes

in peripheral blood by rosette method for detection of, 1494

Immunologic memory, augmentation following treatment

with oxisuran, 1394 stimuli, platelet release reaction induced by,

1201, 1211, 1219 tolerance, to hapten, 1891

Immunosuppression


anti-~ specific, effect on Friend leukemia virus, 1698

concanavalin A in, 63 leukemia virus-induced, 2077

Incubation, spleen cell, reversal of tumor-mediated suppression of immune reactivity by, 1900

Induction antibody synthesis, by solubilized T2 phage and

immunogenic RNA, cellular requirements for, 1981

of cellular immunity to herpes simplex virus, 1019

of hapten-specific delayed hypersensitivity and contact sensitivity, role of lipid in, 1526

of hypergammaglobulinemia, with xenogeneic tumors, 2241

of lysosomal enzyme release by chemotactic factors, 2047, 2055

of specific unresponsiveness against 2,4,6- trinitrophenyl determinant, 1139

of T cell-mediated immunity, 1308 of tolerance

to coccidioidin, 387 to hapten, 1891 to trinitrophenyl, 1891

Infection chlamydial, in patients with lymphogranuloma

venereum and urethritis, fluorescent antibody responses to, 2126

Cryptococcus neoformans, classic and alternate complement pathway roles in host defenses against, 2260

endotoxin-induced, role of iron in nonspecific resistance to, 737

Friend leukemia virus, depression of T cell- mediated cytotoxicity after, 2077

herpes simplex, lymphocyte interferon production and transformation after, 728

lactic dehydrogenase virus immune response to non-viral antigens and,

370 susceptibility to plasmacytoma MOPC-315

and, 1560 Lagos bat virus, 260 Listeria monocytogenes, early response to, 496 Mycoplasma pneumoniae, immune complexes in,

413 pneumococcal capsular polysaccharide produced

during, 2193 Trypanosoma cruzi, phagocytosis and, 1839 Venezuelan equine encephalomyelitis, experi-

mental, antiviral activity of immune spleen cells in, 1070

Inflammation anti-inflammatory effects of tar tar emetic and

niridazole, 222

cell-mediated and foreign body, cholera toxin suppression of, 996

increased, allogeneic effect, 2166 Inhibition

complement biosynthesis, by chemical carcinogens, 1107

macrophage migration abrogation by anti-O antibody and comple-

ment, 1741 T lymphocytes active in, 1815

metabolic, effect on immune response to mycobacterial ribonucleic acid vaccines, 271

migration factor, 1861, 1867 -stimulation, immune, of spontaneous tumors

of various histologic types, 1051 Inhibitory region, of dose-response curve, 1762 Interferon

lymphocyte, production and transformation after herpes simplex infections, 728

mitogen-stimulated, T lymphocyte effector function abnormality in, 617

production by malignant plasma cells from patients with

multiple myeloma, 1131 lymphoid cells required after mitogen stimu-

lation, 1589 T cell, in immunodeficiency, 617

Iron, role in nonspecific resistance to infection induced by endotoxin, 737

Irradiation, anti-KLH antibody formation and, 564

Isoantiserum, synergistic cooperation between immune lymphoid cells and, 2102

Keyhold limpet hemocyanin, antibody formation, effect of irradiation and cyclophosphamide on, 564

Kidney transplant recipients, prospective, antibody-dependent cell-mediated cytotoxicity in, 890

Kinetics, properdin system enzymes, C3b control of, 1115

Lability, acid, of rhinoviruses, 919 Lactic dehydrogenase virus infection

immune response to non-viral antigens and, 370 susceptibility to plasmacytoma MOPC-315 and,

1560 Lagos bat virus, infection with, 260 Lecithin, complement consumption associated

with reaction of C-reactive protein with, 2135

Lens culinaris, hemagglutinin, purification of detergent-solubilized HL-A antigens bv affinity chromatography with, 1190

Lesions, thyroiditis, autoimmune, augmented experimental, production of, 478

1974] INDEX 2303

Leukemia chronic lymphatic, IgD on surface of lympho-

cytes from patients with, 1952 thymus, antigens

isolation of, 1285 synthesis and degradation in presence of

thymus leukemia antiserum, 1296 virus

Friend, 1698, 2077 immunologicalty activated, tumor induction

by, 706 Moloney, 866, 1987

Leukocyte histamine release from, 1757 inhibitory factor, 1461 migration, effect of glutaraldehyde-treated

antigen on inhibition of, 1578 mixed culture, age effect on lymphocyte response

in, 1194 mixed reaction, abnormalities during infectious

mononucleosis, 2278 release of slow reacting substance of anaphylaxis

from, 897 Lipid, in induction of hapten-specific delayed

hypersensitivity, 1526 Lipid-A, interaction of C1, C2, and C4 with, 935 Lipopolysaccharides, bacterial, interaction of

C1, C2, and C4 with, 935 Liposomes, Forssman-containing, complement-

dependent damage due to interaction with a monoclonal IgM, 1949

Listeria monocytogenes infection bone marrow-derived cells in resistance to, 1407 early response to, 496

Lymph node cells

anamnestic response of, 583 antiserum and, production of augmented

experimental autoimmune thyroiditis lesions by combined transfer of, 478

hapten-primed, specificity differences among, 1782

medullary and germinal center proliferative patterns in after regional primary and secondary stimulation with tetanus toxoid, 1961

Lymphocyte(s), see also Cell activated, products of, 1461 activation, biologic expressions of, 1360 antigen-induced proliferation of, in vitro, 746 antigen-reactive, dissociation from antigen-

binding cells in a T lymphocyte enriched population, 1085

anti-lymphocyte serum, immunosuppressive effects in C3-deficient mice, 858

B lymphocytes antigen binding, 1726, 1734

bone marrow, 836 enumeration in peripheral blood by rosette

method for detecting surface-bound immunoglobulin, 1494

histoincompatible T lymphocytes and, cell interactions between, 855

in mixed lymphocyte reaction, 70 purification of, 420 tolerance in, 1158

blastogenesis in response to lymphokines generated in dinitrochlorobenzene-sensitive leukocyte cultures, 1488

blood, peripheral E rosette formation after neuraminidase

treatment of, 1628 enumeration of B lymphocytes by rosette

method for detecting surface-bound immunoglobulins, 1494

thymus-derived lymphocyte identification and quantitation, 520

cyclophosphamide-pret reared, 1594 cytotoxic, induced by orthotopic tooth bud

atlografts, 776 from patients with chronic lymphatic leukemia,

IgI) on surface of, 1952 function, ontogeny, 305 immunoglobutin-bearing, ontogeny, 2202 interferon, production and transformation,

after herpes simplex infections, 728 membrane, ~-mieroglobulin distribution and

mobility on, 2036 mitogen-stinmlated, colony-stimulating factor

production in cultures of, 502 mixed

interaction, early detection, 1426 reaction, T and B lymphocytes in, 70

Moloney virus-transformed, failure of terminal complement components to induce lysis of, 866

peripheral mitogenic effect of a water soluble extract of

Nocardia opaca on, 2028 tuberculin-stimulated, migration inhibitory

factor produced by phytohemagglutinin and, 675

peritoneal exudate, 1085 plasma membranes, 249 proliferation, BrdU effect on, 1705 receptors, for myxoviruses and paramyxo-

viruses, 2176 response, in mixed leukocyte culture, to phyto-

hemagglutinin, and in graft-vs-host reaction, effect of age on, 1194

responsiveness, in immunodeficiency, membrane receptors and, 376

sensitized, early appear'race in mice infected with Listeria monocytogenes, 496


stimulation after immunization with live and inactivated

rabies vaccines, 2013 early detection, 1426

T lymphocytes antigen binding, 293, 1726, 1734 bone marrow, 836 cytotoxic, in lymphocytic choriomeningitis,

1548 effector function in immunodeficiency dis-

eases, 617 -enriched population, dissociation of antigen-

reactive lymphocytes from antigen-binding cells in, 1085

histoincompatible B lymphocytes and, cell interactions between, 855

identification and quantitation, 520 immune, rnacrophage control of time-depend-

ent changes in antigen sensitivity of, 359 in lymphocyte transformation, 1815 in macrophage migration inhibition, 1815 in mixed lymphocyte reaction, 70 in primary humoral antibody response to

brucellin, 716 in rats, 79, 87 purification of, 420 receptors for erythrocytes, 862 sarcoma virus-induced tumor rejection and,

533 subpopulations, 333, 1971

transformation periodate=induced, 1884 T lymphocytes active in, 1815

trapping, thymus dependence of, lCl Lymphocytic choriomeningitis, cytotoxic thymus-

derived lymphocytes in, 1548 Lymphogranuloma venereum, fluorescent anti-

body responses to chtamydial infection in patients with, 2126

Lymphoid cell(s), see a l s o Lymphocyte B and T, delineation of, 444 C3 receptors on, 1766 immune, synergistic cooperation between iso-

antiserum and, 2102 line, migration inhibitory factor produced by,

675 -mediated cytotoxicity, antibody-dependent,

complement in, 398 required for interferon production after mitogen

stimulation, 1589 separation, 1231

Lymphoid organs, immunoglobulin receptors and antibody-dependent cell cytotoxicity in, 37

Lymphoid tissue, bronchus-associated, proliferative response after local and systemic immunization, 1997

Lymphokines, 540

circulating monocyte levels and delayed skin reactivity and, 1540

in allergic contact dermatitis, 1488 Lymphoma cell

autoantibodies detected by lysis of, 320 induction to produce specific phage neutraliz-

ing antibody, 1415 Lymphopoietic potential, of bone marrow cells

from aged mice, 1244 Lymphotoxin

antigen-induced, 1347 assay for, 2111 mitogen-induced, 1347 molecular dimensions, 168

Lysis complement binding without, 866 DBA/2 lymphoma cell, autoantibody detection

by, 320 Moloney virus-transformed lymphocyte, failure

of terminal complement components to induce, 866

target cell, antibody-mediated, by nonimmune cells, 792

Lysosomal enzyme release, induction by chemotactic factors, 2047, 2055

Macrophage -associated antigen, 746, 1804 -associated esterases, enhancement of migration

inhibition factor by inhibition of, 1571 control of time-dependent changes in antigen

sensitivity of immune T lymphocyte populations, 359

function in immune responses, 1181 migration inhibition

abrogation by anti-0 antibody and complement, 1741

T lymphoeytes active in, 1815 receptors for migration inhibitory factor, migra-

tion stimulatory factor, and agglutinating factor, 1867

Mamlnary neoptasia, serum factors in, 439 tumor, virus-induced, immune responses to, 693

Marker, antigenic, IgG, detected by 19S anti-IgG in streptocoecM antisera, 627

Marrow bone, see Bone marrow grafts

abrogation of sensitization by procarbazine and antithymocyte serum, 1508

effect of prior blood transfusions on, 1508 Mast cell, see Cell, mast Medullary proliferation patterns in lymph nodes

after primary and secondary stimulation with tetanus toxoid, 1961

Membrane

1974] INDEX 2305

antigen blocking of cell-mediated cytolysis, 926 cytomegMovirus-specific, 1680

basement, renal, autoantibodies to, 241 cyst, Echinococcus granulosus, blood P1 active

carbohydrate antigen of, 1061 lymphocyte, fl2-microgtobulin distribution and

mobility on, 2036 plasma

antigenic constituent on thymus cells, 249 lymphocyte, 249

receptors, lymphocyte responsiveness in immunodeficiency and, 376

Memory, immunologic, augmentation following treatment with oxisuran, 1394

Menadione binding, sulfhydryl-containing heavy chain peptide of protein 460 affecting, 96

Meningitis, see Choriomeningitis Metabolic inhibitors, effect on immune response

to mycobacterial ribonucleic acid vaccines, 271

Metabolism, cellular antigen, specific antisera effect on, 1285, 1296

Microglobulin, fl~- distribution and mobility on lymphocyte mem-

brane, 2036 production by hematopoietic, mesenchymal,

and epithelial cells, 137 Migration

inhibition, macrophage abrogation by anti-~ antibody and comple-

ment, 1741 T lymphocytes active in, 1815

inhibitory factor, 1461, 1861 1867 enhancement by inhibition of macrophage-

associated esterases, 1571 glutaraldehyde-treated antigen effect on, 1578 macrophage receptors for, 1867 produced by lymphoid cell line and phyto-

hemagglutinin and tuberculin-stimulated peripheral lymphocytes, similarity of, 675

stimulation factor, 1861, 1867 Mitogens

immune stitnulation of protein synthesis in cells responding to, 47

-induced lymphocyte proliferation, 1705 -induced lymphotoxin, 1347 -stimulated interferon, T lymphocyte effector

function abnormality in, 617 -stimulated lymphocyte cultures, colony-stimu-

lating factor production in, 502 stimulation, lymphoid cells required for inter-

feron production after, 1589 T cell, bone marrow T cell response to, 960

Mitogenesis, in endotoxin-stimulated spleen cells, 770

Mitogenic effect

of NaIO4 treated lymphocytes upon autologous lymphocytes, 1884

of water soluble Nocardia opaca extract., 2028 Motoney leukemia virus

sarcoma cells, complement-dependent cytotoxic antibodies to, 1987

-transformed lymphocytes, failure of terminal complement components to induce lysis of, 866

Monocyte levels, lymphokme activity and, 1540 percentage among mononuclear cell fractions

from normal blood, 234 Mononucleosis, infectious, mixed leukocyte reac-

tion abnormalities during, 2278 MOPC

104E, plasmacytoma, rate of release of IgM from, 266

-315, plasmacytoma, susceptibility to after infection with lactic dehydrogenase virus, 1560

Mycobacterial RNA, effect of metabolic inhibitors and hydroxylamine on immune response to, 271

Mycobacterium tuberculosis, cell-mediated immunity to, 1322

Mycoplasma pneurnoniae, immune complexes in, 413

Mycoplasma pulmonis, immune response to, 124 Myelin basic protein, homologous, treatment of

experimental allergic encephalomyelitis with, 392

Myeloma cells, induction to produce specific phage neu-

tralizing antibody, 1415 immunogtobulins, binding activity, 1565 multiple, interferon production by malignant

plasma cells from patients with, 1131 proteins

IgA, glycopeptides of heavy chains from, 1623 IgA1, with carboxy-terminal deletion, 1517 IgG2 and IgA1, in a single patient, 871

Myxoviruses, lymphocyte receptors for, 2176

Neoplasia, mammary, serum factors in, 439 Neuraminidase, E rosettes and, 1628 Neutrophil

cholinergic stimulation of phagocytic enzyme release from, 210

granule enzymes in chronic granulomatous disease, exocytosis of, 1383

Niridazole, anti-inflammatory effects, 222 Nocardia opaca, mitogenic effect of a water soluble

extract of, 2028

Opsonic defect, familial, C5 abnormality in, 1164


Opsonins, heat labile, staphylococcal protein A and, 1177

Otitis, media, secretory ~A and middle ear impli- cations in, 488

Oxisuran, immunologic memory augmentation following treatment with, 1394

Paralysis, low dose, suppressor T cell role in development of, 2020

Paramyxoviruses, lymphocyte receptors for, 2176 Passive hemaggtutination assay, see Assay, pas-

sive hemagglutination Patches, Peyer's, see Peyer's patches Pathway

complement, see Complement, pathway properdin, interaction with pneumococci, role

of immunoglobulin in, 1635 Peptide, heavy chain, sulfhydryl, protein 96, 460 Periodate-induced lymphocyte transformation,

1884 Peritoneal exudate lymphocyte, 1085 Peroxidase, horseradish, commercial, potent non-

peroxidase glycoprotein immunogen in, 1094 Peyer's patches, ontogency, 555 pH, acid, IgE dissociation from basophil receptors

at, 1078 Phage

neutralizing antibody, induction of myeloma and lymphoma cell cultures to produce, 1415

T2, solubilized, cellular requirements for antibody synthesis induction by, 1981

Phagocytic enzyme release, cholinergic stimulation of, 210

Phagocytosis, as defense mechanism against Trypanosoma cruzi infection, 1839

Phosphatides, choline, complement consumption associated with reaction of C-reactive protein with, 2135

Phosphorylcholine, immune response to, 1747 Phosphotidylserine enhancement of antigen-

induced mediator release from mast cells, 970

Phytohemagglutinin age effect on lymphocyte response to, 1194 bone marrow T cell response to, 960 effect on histocompatibility antigens, 852 migration inhibitory factor produced by tuber-

culin-stimulated peripheral lymphocytes and, 675

reactivity elevation in fetal thymocytes, 305 responses, antigen suppression of, 215 -responsive T cells, thymidine suicide of, 333

Plaque assay

for detecting alloantibody-producing cells, 2251

hemolytic, micro4echnique for, 1271

-rosette, 1782 -forming cell responses, see Response, plaque-

forming cell Plasma

anti-plasma cell serum, effect on B cells, 462 cells, malignant, interferon production by, from

patients with multiple myeloma, 1131 membrane

antigenic constituent on thymus cells, 249 lymphocyte, 249

Plasmacyte antigenic determinant, new, 911 -thymocyte, common antigen, 1774

Plasmacytomas cellular basis of immunodepression in mice

with, 2068 MOPC 104E, rate of release of IgM from, 266 MOPC 315, susceptibility to after infection with

lactic dehydrogenase virus, 1560 Platelet release reaction, induced by immunologic

stimuli, 1201, 1211, 1219 Pneumococcal polysaccharide

C-, consumption of complement associated with reaction of C-reactive protein with, 2135

capsular, produced during human infection, 2193 Type III , antibody response to, 404, 1042, 2020

Pneumococci IgG Fc and, 1955 interaction with properdin pathway, role of

immunoglobulin in, 1635 Polyadenine:polyuridine, effect on brucellosis,

1535 Polypeptide, major, primate type C virus, 1250 Polyribitol-phosphate, cross-reaction with capsu-

lar polysaccharide of Haemoph i lus in f lu-

enzae type B, 649 Polysaccharide, see Pneumococcal polysaccharide;

Polyribitol-phosphate Precipitation

allotypic antigen complement-dependent, 830 ammonium sulfate, determination of soluble

immune complex molar composition and antibody association constants by, 451

Pregnancy, normal, immune complex in renal glomerulus during, 186

Priming, for an IgM response, kinetics of, 1582 Procarbazine, abrogation of sensitization to

marrow graft by, 1508 Proenzyme form of Cls, isolation and charac-

terization, 339 Proliferation inhibitory factor, production by

spleen cells, 1435 Proliferative response, see Response, proliferative Properdin

convertase activity, in alternate pathway of complement activation, 56

1974] INDEX 2307

pathway, interaction with pneumococci, role of immunoglobulin in, 1635

system~ enzymes, kinetics, C3b control of, 1115 zymosan reaction with, 1845

Protease immunosuppressive, chymopapain C, 1660 neutral, cholinergic stimulation of phagocytic

release of, 210 Protein, see also Glycoprotein

A, staphylococcal, heat labile opsonins and, 1177 basic myelin, homologous, treatment of experi~

mental allergic encephalomyelitis with, 392 C-reactive, interaction with complement sys-

tem, 2135 460, hapten-binding region of, 96 monoclonal, IgA and IgG, 201 myeloma

IgA, glycopeptides of heavy chains from, 1623 IgAi, with carboxy-terminal deletion, 1517 IgG~ and IgA1, in a single patient, 871

purified derivative of tuberculin (PPD) antigen and, 151 effect on specific immune response to heterol-

ogous red cells in vitro, 151 Ss, localization and synthesis sites, 2210 synthesis

assay, semimicro, detection of lymphocyte stimulation and mixed lymphocyte interaction with, 1426

immune stimulation in T and B cells, 47 Proteolysis, resistance of serum and secretory

IgA to, 949

Rabies serogroup, Lagos bat virus, 260 vaccines, live and inactivated, lymphocyte

stimulation after, 2013 Radioimmunoassay

quantitation of antigen-antibody reactions by, 1008

solid phase, for diagnosis of hydatidosis, 1674 Radioresistance, of antibody-forming system at

advanced stages of the secondary response to tetanus toxoid, cellular bases for, 2154

Ragweed antigen E, polymerized, 1855 Reaction

antigen-antibody, quantitation by radioimmunoassay, 1008

graft-vs-host age effect on lymphocyte response in, 1194 anti-host antibodies in, 410 cellular immunity in, 706 glomerulonephritis in, 410

mixed leukocyte, abnormalities during infectious mononucleosis, 2278

mixed lymphocyte, T and B lymphocytes in, 70

platelet, release, induced by immunologic stimuli, 1201, 1211, 1219

Reactivity immune

reversal of tumor-mediated suppression of, 1900

stimulation of early protein synthesis as assay of, 47

skin delayed, lymphokine activity and, 1540 thymocyte

to atlogeneic cells, 305 to phytohemagglutinin, 305

Reagin-producing cells in spleen and bone marrow of immunized mice, 1609

Receptors basophil, IgE dissociation from at acid pH, 1078 blockade, by tolerogen, 1793 complement, B cell, immunoglobulin and, 1931 immunoglobulin, in lymphoid organs, 37 lymphocyte

for erythrocytes, 862 for myxoviruses and paramyxoviruses, 2176

membrane, lymphocyte responsiveness in immunodeficiency and, 376

Release antibody, from tumor cells, 266 5~Cr-endotoxin, from bacteria as an assay of

serum bactericidal activity, 2184 enzyme

lysosomal, induction by chemotactic factors, 2047, 2055

phagocytic, cholinergic stimulation of, 210 histamine

ATP and, 664 cyclic AMP and, 511,664 from leukocytes, divalent requirement, 1757 inhibitory region of dose-response curve, 1762

IgM, from MOPC 104E plasmacytoma, rate of, 266

mediator, from mast cells, antigen-induced, phosphotidylserine enhancement of, 970

platelet, reaction, induced by immunologic stimuli, 1201, 1211, 1219

stow reacting substance of anaphylaxis, from leukocytes, 897

Renal basement membrane, autoantibodies to, 241 complications, of babesiosis, 1 cortical tubulointerstitial disease, in absence

of C4, 1387 glomerulus, immune complex during normal

pregnancy, 186 Resistance, see also Radioresistance

to proteolysis, IgA, 949 Response

anamnestic cell collaboration in, 583


IgM, to haptenic determinant DNP on a thymus-independent carrier, 427

antibody anti-KLH, 564 cellular cooperation and soluble factors in,

1149 fluorescent, to clamydial infection in patients

with lymphogranuloma venereum and urethritis, 2126

homocytotropic, hapten-specific, antigen- specific inhibitory T cell factor in, 783

humoral, primary, to brucellin, T lymphocytes in, 716

priming for, 1582 regulation in vitro, 1685 suppression, concanavatin A in, 63 to bifunctional antigens, 883 to pneumococcal polysaccharide Type I I I ,

404, 1042, 2020 early, to Listeria monocytogenes infection, 496 host, to tumor-associated fetal antigens, 1026 immune, see also Innnunity

antibody affinity and, 1255 carrier-specific enhancement of using antigen-

antibody complexes, 804 cellular, 693, 1477, 2166 chymopapain C effect on, 1660 genetic control of, 1329 humoral, to herpes simplex virus, 1019 IgA, to TNP determinant group, 812 IgM, 427, 812, 1582 increased binding affinity of 19S and 7S anti-

DNP antibodies during, 2227 macrophage function in, 1181 of cultured spleen cells to erythrocytes, 326 primary, humoral factors in initiating, 1873 rifamycin-SV derivatives and, 844 to bifunctional antigens, 883 to heterologous red cells in vitro, purified

protein derivative of tuberculin effect on, 151

to mycobacterial ribonucleic acid, effect of metabolic inhibitors and hydroxylamine on, 271

to Mycoplasma pulmonis, 124 to non-viral antigens, lactic dehydrogenase

virus infection and, 370 to phosphorylcholine, 1747 to polymerized ragweed antigen E, 1855 to thyroiditis, genetic control of, 965 tumor, cytotoxic, 1718

iimnunocyte, to purified bacterial toxin (choleragen) and toxoid, 1452

inflammatory cell-mediated and foreign body, cholera toxin

suppression of, 996

increased, allogeneic effect, 2166 lymphocyte, in mixed leukocyte culture, to

phytohemagglutinin, and in graft-vs-host reaction, effect of age on, 1194

phytohemagglutinin, antigen suppression of, 215 plaque-forming cell, suppression in vitro by

supernatant fluids from concanavalin A- activated spleen cell cultures, 1360

proliferative of bronchus-associated lymphoid tissue, after

local and systemic immunization, 1997 of medullar and germinal center in lymph

nodes, after regional primary and secondary stimulation with tetanus toxoid, 1961

secondary to erythrocytes, discontinuous antibody secre-

tion during, 1602 to tetanus toxoid, cellular bases for relative

radioresistance of the antibody-forming system at advanced stages of, 2154

Reticuloendothelial system, saturation with soluble immune complexes, 1939

Rheumatoid factor, interaction with infectious vaccinia virus-antibody complexes, 2087

Rhinovirus, acid lability of, 919 Ribonucleic acid, see RNA Rifamycin-SV, derivatives, immune response and,

844 RNA

immunogenic, cellular requirements for antibody synthesis induction by solubilized T2 phage and, 1981

myeobacterial, effect of metabolic inhibitors and hydroxylamine on immune response to, 271

Rosette E, neuraminidase and, 1628 method, for detecting surface-bound immuno-

globulin, enumeration of B lymphocytes in peripheral blood by, 1494

-plaque assay, 1782

Sarcoma cells, Motoney, complement-dependent cyto-

toxic antibodies to, 1987 virus-induced tumors

effector cell diversity in, 1477 immunity to, 1477, 1815, 1826 T lymphocyte in vivo protection against, 533

Saturation, reticuloendothelial system, with soluble immune complexes, 1939

Schistosomiasis, circulating antigen in, 1500 Secretion, antibody, discontinuous, during sec-

ondary response to erythrocytes, 1602 Secretory component, free and bound, differential

localization of, 1553 Sensitivity, see also Hypersensitivity

1974 INDEX 2309

antigen, of immune T lymphocytes, macrophage control of time-dependent changes in, 359

contact, role of lipid in induction of, 1526 tolerance and contact, to DNFB, 115, 849

Sensitization passive, mechanisms of, 1078 to marrow graft, abrogation by procarbazine

and antithymocyte serum, 1508 Separation, lymphoid cell, 1231 Serum

adenovirus type-specific anti-hemagglutinin, counterimmunoelectrophoresis with, 987

aging mice, homogeneous immunoglobulins in, 2271

anti-H-2, inhibition of antigen binding to T and B cells by, 1734

anti-imnmnoglobulin, inhibition of antigen binding to T and B cells by, 1734

anti-lymphocyte, immunosuppressive effects in C3-deficient mice, 858

antiserum antibodies specific for 0- and Ly-Mloantigens

in, 683 anti-~, Friend virus leukemia and, 1698 blocking, of cell-mediated cytolysis, 1308 isoantiserum, synergistic cooperation between

immune lymphoid cells and, 2102 lymph node cells and, production of aug-

mented experimental thyroiditis lesions by combined transfer of, 478

metabolism of, cellular antigens and, 1285, 1296

streptococcal, IgG antigenic marker detected by 19S anti-IgG in, 627

thymus leukemia, synthesis and degradation of thymus leukemia antigens in presence of, 1296

thyroglobulin, protection against autoimmune thyroiditis by, 468

to cytomegMoviruses, use in immunofluorescence and complement fixation tests, 528

anti-sulfatide, preparation and properties of, 424 anti-thymocyte

abrogation of sensitization to marrow grafts by, 1508

interaction with hematopoietic stem cells, 822 bactericial activity, release of 51Cr-endotoxin

from bacteria as an assay of, 2184 -blocking factors, associated with IgG, 1267 cell

anti-plasma, effect on B cells, 462 epidermal, tissue-specific differentiation anti-

gens in, 311 factor

assay, enhancement and antagonism of spleen cell activity in vitro in mammary neoplasia detected by, 439

in mammary neoplasia, 439 fractionation by DEAE cellulose chromatog-

raphy, 1267 HL-A, purification of, 1124 IgA, resistance to proteolysis, 949 plasmacyte, new antigenic determinant on, 911 serogroup, rabies, Lagos bat virus, 260

Sialadenitis, autoallergic, experimental, induction of, 178

SjSgren's syndrome, see Syndrome, SjSgren's Skin reactivity, delayed, lymphokine activity

and, 1540 Specificity, carrier

cross-stimulation i n vitro, 1354 cross-tolerance in vivo, 1354

Sphingomyelin, complement consumption associated with reaction of C-reactive protein with, 2135

Spleen cell

activity in mammary neoplasia, 439, 693 adherent, antibody-forming cell precursors in,

430 antiviral activity in experimental Venezuelan

equine encephalomyelitis infection, 1070 concanavalin A-activated, suppression of

plaque-forming cell responses in vitro by supernatant fluids from, 1360

cultured, immune response to erythrocytes, 326

endotoxin-stimulated, 770 immune or nonimmune, antibody interaction

with cytotoxic effector cells in, 2219 incubation, reversal of tumor-mediated sup-

pression of immune reactivity by, 1900 proliferation inhibitory factor production by,

1435 reaginic antibody-forming, 1609

localizing thymocytes, immuno-regutatory role of, 546

mitogenic effect of a water soluble extract of Nocardia opaca on, 2028

Staphylococcal protein A, heat labile opsonins and, 1177

Stimulation cell, detection of tolerance and contact sensi-

t iv i ty to DNFB by, 115 cholinergic, of phagocytic enzyme release, 210 cross-stimulation, carrier, specificity of, 1354 immune, of protein synthesis in T and B cells, 47 -inhibition, immune, of spontaneous tumors of

various histologic types, 1051 lymphocyte

after immunization with live and inactivated rabies vaccines, 2013

early detection, 1426 migration factor, 1861, 1867

2310 1NDEX [VOL. 112

mitogen, lymphoid cells required for interferon production after, 1589

with tetanus toxoid, medullary and germinal center proliferative patterns in lymph nodes after, 1961

Streptococcal antisera, IgG antigenic marker detected by 19S anti-IgG in, 627

Suicide, thymidine, of PHA-responsive T cells, 333 Sulfhydryl peptide, protein, 96, 460 Supernatant fluids from concanavalin A-activated

spleen cell cultures, suppression of plaque- forming cell responses in vitro by, 1360

Suppression of cell-mediated and foreign body inflammatory

responses by cholera toxin, 996 of phytohemagglutinin responses by antigen, 215 of plaque-forming cell responses in vitro by

supernatant fluids from concanavalin A- activated spleen cell cultures, 1360

T cell-mediated immunity, b'y cells from progressor animals, 1826

tumor-mediated, of immune reactivity, reversal of, 1900

Susceptibility, to cutaneous anaphylaxis, 1369 Swelling, ear, detection of tolerance and contact

sensitivity to DNFB by, 115 Syndrome, Sj6gren's, mononuclear cell infiltra-

tion of minor salivary glands in, 641 Synergistic cooperation, between isoantiserum

and immune lymphoid cells, 2102 Synthesis, see also Biosynthesis

antibody control of, 1255 induction, by solubilized T2 phage and im-

munogenic RNA, cellular requirements for, 1981

protein assay, semimicro, detection of lymphocyte

stimulation and mixed lymphocyte interaction with, 1426

immune stimulation in T and B cells, 47 thymus leukemia antigens in presence of thymus

leukemia antiserum, 1296

Tartar, emetic, anti-inflammatory effects of, 222 Technetium-99m-labeled erythrocytes, hemolysis

of, 756 Test

complement fixation, antisera to cytomegaloviruses used in, 528

immunofluorescence, antisera to cytomegaloviruses used in, 528

Tetanus toxoid medullary and germinal center proliferative

patterns in lymph nodes after regional primary and secondary stimulation with, 1961

secondary response to, cellular bases for relative radioresistance of the antibody-forming system at advanced stages of, 2154

Thymidine suicide, of PHA-responsive T cells, 333 Thymocyte

anti-thymocyte serum abrogation of sensitization to marrow graft

by, 1508 interaction with hematopoietic stem cells, 822

fetal, elevation of reactivity to allogeneic cells and phytohemagglutinin in, 305

-plasmacyte, common antigen, 1774 spleen localizing, immuno-regulatory role of, 546

Thymocytotoxic antibody, immunofluorescence studies on, 285

Thymus cells, see also Cells, T cells; Lymphocytes, T

lymphoeytes antigenic plasma membrane constituent on,

249 dependence of lymphocyte trapping, 101 -dependent lymphocytes, in rats, 79, 87 -derived lymphocytes

cytotoxic, in lymphocytic choriomeningitis, 1548

identification and quantitation, in peripheral blood, 520

-derived-suppressor cells, action in antibody response to Type I I I pneumococcal polysaccharide, 404

-independent carrier, IgM anamnestie immune response to haptenic determinant DNP on, 427

-leukemia antigens isolation of, 1285 synthesis and degradation in presence of

thymus leukemia antiserum, 1296 Thyroglobulin, protection against autoimmune

thyroiditis by, 468 Thyroiditis, autoimmune

augmented experimental, production of, 478 genetic control of, 965 thyroglobulin protection against, 468

Time-dependent changes in antigen sensitivity of immune T lymphocyte populations, macrophage control of, 359

Tissue(s) gut-associated lymphoepithelial (GALT), im-

munoglobulins and, 555 lymphoid, bronchus-associated, proliferative

response after local and systemic immunization, 1997

-specific antigens, in epidermal cell sera, 311 TNP

IgM and IgA immune response to, 812 2,4, 6-trinitrophenyl determinant, unresponsive-

ness induction against, 1139

1974 INDEX 2311

Togaviruses, antigenically related, specificity of IgM and IgG antibodies after challenge with, 656

Tolerance cellular basis for, 107 cellular events in, 1354 cross-tolerance, carrier, specificity of, 1354 in B lymphocytes, 1158 induction

to coccidioidin, 387 to hapten, 1891 to trinitrophenyl, 1891

sensitivity to DNFB, 115, 849 Tolerant cell, receptor blockade by tolerogen, 1793 Tolerogen, receptor blockade of, 1793 Tooth

alloimmunity against, 776 orthotopic allografts, cytotoxic antibodies and

lymphocytes induced by, 776 Toxin

cholera, suppression of cell-mediated and foreign body inflammatory responses, 996

purified bacterial (choleragen), immunity to, 1452

Toxoid, tetanus medullary and germinal center proliferative

patterns in lymph nodes after regional and secondary stimulation with, 1961

secondary response to, cellular bases of relative radioresistance of the antibody-forming system of advanced stages of, 2154

Trachoma, delayed hypersensitivity to, 540 Transfer, combined, of antiserum and lymph node

cells, production of augmented experimental autoimmune thyroiditis lesions by, 478

Transformation, lymphocyte periodate-induced, 1884 T lymphocytes active in, 1815

Transfusions, blood, prior, effect on marrow grafts, 1508

Transplant, kidney, prospective recipients, antibody-dependent cell-mediated cytotoxicity in, 890

Trapping, lymphocyte, thymus dependence of, 101 Trinitrophenyl, tolerance induction to in B cells,

1891 Trypanosorna cruzi infection, phagocytosis and,

1839 Trypsin

al-anti t rypsin, binding to IgA, 2274 C3 activation and conversion by, 1444

Tuberculin purified protein derivative

antigen and, 151 effect on specific immune response to heterol-

ogous red cells in vitro, 151 -stimulated peripheral lymphocytes, migration

inhibitory factor produced by phytohemagglutinin and, 675

Tuberculosis, cell-mediated immunity to, 1322 Tumor

-associated fetal antigens, host response to, 1026 cells, measurement of antibody release from,

266 immune response, cytotoxic, 1718 immunity

lactic dehydrogenase virus infection and, 1560 induction, by immunologically activated leu-

kemia virus, 706 mammary, virus-induced, immune responses to,

693 -mediated suppression of immune reactivity,

reversal of, 1900 regressing, immune T cells in mice with, 1815 sarcoma virus-induced

effector cell diversity in cellular immune response to, 1477

immunity to, 1815, 1826 T lymphocyte in vivo protection against, 533

spontaneous, of various histologic types, immune stimulation-inhibition of, 1051

xenogeneic, induction with hypergammaglobulinemia, 2241

Unresponsiveness, induction, against 2,4,6-trinitrophenyl determinant, 1139

Urethritis, fluorescent antibody responses to chlamydial infection in patients with, 2126

Vaccinia virus, -antibody complexes, interaction of rheumatoid factor with, 2087

Vaccine mycobacterial RNA, metabolic inhibitor effect

on immune response to, 271 rabies, live and inactivated, lymphocyte stimu-

lation after, 2013 Variable region

heavy chain of IgG~ k and IgA~ ~ myeloma proteins, similarities in a single patient, 871

light chain, sequence restriction in, 633 Venezuelan equine encephalomyelitis infection,

experimental, antiviral activity of immune spleen cells in, 1070

Vessels, blood, brain, adsorption properties in vitro and in vivo of antibodies raised against, 6O7

Virus adenovirus, type-specific anti-hemagglutinin

sera, counterimmunoelectrophoresis with, 987

antiviral activity of immune spleen cells in experimental Venezuelan equine encephalomyelitis infection, 1070


cytomegalovirus, antisera to, use in immunofluorescence and complement fixation tests, 528

herpes simplex cellular immunity to, 1019 humoral immunity to, 1019 lymphocyte interferon production and trans-

formation after, 728 lactic dehydrogenase infection

immune response to non-viral antigens and, 370

susceptibility to plasmacytoma MOPC-315 and, 1560

Lagos bat, infection with, 260 leukemia

Friend, 1698, 2077 immunologically activated, tumor induction

by, 706 Moloney, 866, 1987

mammary tumor, induced tumors, immune responses to, 693

myxoviruses, lymphocyte receptors for, 2176

paramyxoviruses, lymphocyte receptors for, 2176

rhinovirus, acid lability, 919 sarcoma-induced tumors

effector cell diversity in cellular immune response to, 1477

immunity to, 1815, 1826 T lymphocyte in vivo protection against, 533

togaviruses, antigenically related, specificity of IgM and IgG antibodies after challenge with, 656

type C primate, major polypeptide, 1250 vaccinia, infectious, antibody complexes, inter-

action of rheumatoid factor with, 2087 Venezuelan equine encephalomyelitis, experi-

mental, antiviral activity of immune spleen cells in, 1070

Zymosan -induced platelet release reaction, 1211, 1219 kinetic studies of properdin system enzyme

formation on, 1115 reaction with properdin system, 1845

SODIUM M TRIZOATE

SOLUTION (ISOPAQUE) For preparation of pure lymphocyte suspensions

Blood

Separation fluid

Before After

Before and after centrifugatlon

Lymphocytes

R eferences

Boyum, A. (1964): Separation of white blood cells. Nature 204, 793.

Boyum, A. (1968): Separation of leucocytes from blood and bone marrow. Scand. J. Clin. Lab. Invest. 21, Suppl. 97.

Favour, C, B (1964): Antigen-antibody reactions in tissue culture. Immunological Methods, ed, J, R. Ackroyd, pp, 195-223. Blackwell Scientific Publ., Oxford,

Thorsby, E & Bratlie, A, (1970). A rapid method for preparation of pure lymphocyte suspensions. Histocompatibility Testing 1970, ed. P,I. Terasaki, p. 655 Munksgaard, Copenhagen.

A T LAST/

Available in the U.S.A.!

GALLARD-SCHLESINGER CHEMICAL MFG. CORP., 582 MINEOLA AVE., CARLE PLACE

LI., N.Y, 11514 m(516) 333-5600

GallardlScldesiqer

~Bacto ~ Febrile Antigen Set includes.~ ~ . , . n ....

. . . . • i i l l ¸ ~!~

;! i~i!~ ~ ~;i! i!i]! ¸̧ ¸̧ ̧

NEGATIVE

CONTROL

( !

These controls insure confidence in the performance of your Febrile Test results. Set consists of six

basic antigens with polyvalent positive and negative controls--includes four Salmonella antigens for slide

and tube tests plus B, abortus and Proteus 0X19.

Widest range of antigens and antisera available,

For more information, write for literature number 0261.

The Editorial Staff of the Journal o/Immunology is grateful to the many ad hoc reviewers who served...

Documents

Transcript of The Editorial Staff of the Journal o/Immunology is grateful to the many ad hoc reviewers who served...